


RESEARCH ARTICLE

Genome-wide analysis of ivermectin response by *Onchocerca volvulus* reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity

Stephen R. Doyle^{1,2*}, Catherine Bourguinat³, Hugues C. Nana-Djeunga^{4,5}, Jonas A. Kengne-Ouafo⁶, Sébastien D. S. Pion⁷, Jean Bopda⁸, Joseph Kamgno^{5,8}, Samuel Wanji⁶, Hua Che³, Annette C. Kuesel⁹, Martin Walker¹⁰, Maria-Gloria Basáñez¹⁰, Daniel A. Boakye¹¹, Mike Y. Osei-Atweneboana¹², Michel Boussinesq⁷, Roger K. Prichard^{3*}, Warwick N. Grant^{1*}



OPEN ACCESS

Citation: Doyle SR, Bourguinat C, Nana-Djeunga HC, Kengne-Ouafo JA, Pion SDS, Bopda J, et al. (2017) Genome-wide analysis of ivermectin response by *Onchocerca volvulus* reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Negl Trop Dis 11(7): e0005816. <https://doi.org/10.1371/journal.pntd.0005816>

Editor: Thomas R. Unnasch, University of South Florida, UNITED STATES

Received: January 17, 2017

Accepted: July 19, 2017

Published: July 26, 2017

Copyright: © 2017 Doyle et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Relevant data is available in the figures and supporting text. Sequence data are archived at the European Nucleotide Archive (ENA) under the study accession PRJEB17785. <https://www.ncbi.nlm.nih.gov/bioproject/PRJEB17785> <http://www.ebi.ac.uk/ena/data/view/PRJEB17785>.

Funding: This investigation received financial support from UNICEF/UNDP/World Bank/World

1 Department of Animal, Plant and Soil Sciences, La Trobe University, Bundoora, Australia, **2** Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom, **3** Institute of Parasitology, McGill University, Sainte Anne-de-Bellevue, Québec, Canada, **4** Parasitology and Ecology Laboratory, Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon, **5** Centre for Research on Filariasis and other Tropical Diseases (CRFiMT), Yaoundé, Cameroon, **6** Research Foundation in Tropical Diseases and the Environment (REFOTDE), Buea, Cameroon, **7** Institut de Recherche pour le Développement (IRD), IRD UMI 233 TransVIHMI – Université Montpellier – INSERM U1175, Montpellier, France, **8** Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, **9** UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (WHO/TDR), World Health Organization, Geneva, Switzerland, **10** London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London, United Kingdom, **11** Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana, **12** Department of Environmental Biology and Health Water Research Institute, Council for Scientific and Industrial Research (CSIR), Accra, Ghana

* These authors contributed equally to this work.

* Current address: London Centre for Neglected Tropical Disease Research, Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, United Kingdom

* sd21@sanger.ac.uk (SRD); roger.prichard@mcgill.ca (RKP); w.grant@latrobe.edu.au (WNG)

Abstract

Background

Treatment of onchocerciasis using mass ivermectin administration has reduced morbidity and transmission throughout Africa and Central/South America. Mass drug administration is likely to exert selection pressure on parasites, and phenotypic and genetic changes in several *Onchocerca volvulus* populations from Cameroon and Ghana—exposed to more than a decade of regular ivermectin treatment—have raised concern that sub-optimal responses to ivermectin's anti-fecundity effect are becoming more frequent and may spread.

Methodology/Principal findings

Pooled next generation sequencing (Pool-seq) was used to characterise genetic diversity within and between 108 adult female worms differing in ivermectin treatment history and response. Genome-wide analyses revealed genetic variation that significantly differentiated good responder (GR) and sub-optimal responder (SOR) parasites. These variants were not

Health Organization Special Programme for Research and Training in Tropical Diseases (WHO/TDR); Agence Nationale pour la Recherche, France (Grant: ANR-06-SEST-32); the Wellcome Trust, UK (Grant: 092677/Z/10/Z); the Natural Sciences and Engineering Research Council of Canada (Grant: RGPIN/2777-2012), Fonds de Recherche du Québec – Nature et technologies (FQRNT), Canadian Institutes of Health Research (CIHR grants: 85021 and 94593); Centre of Host-Parasite interaction (CHPI), Quebec; an Early Career Development Fellowship from La Trobe University (SRD); and computational resources from the Victorian Life Sciences Computation Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

randomly distributed but clustered in ~31 quantitative trait loci (QTLs), with little overlap in putative QTL position and gene content between the two countries. Published candidate ivermectin SOR genes were largely absent in these regions; QTLs differentiating GR and SOR worms were enriched for genes in molecular pathways associated with neurotransmission, development, and stress responses. Finally, single worm genotyping demonstrated that geographic isolation and genetic change over time (in the presence of drug exposure) had a significantly greater role in shaping genetic diversity than the evolution of SOR.

Conclusions/Significance

This study is one of the first genome-wide association analyses in a parasitic nematode, and provides insight into the genomics of ivermectin response and population structure of *O. volvulus*. We argue that ivermectin response is a polygenically-determined quantitative trait (QT) whereby identical or related molecular pathways but not necessarily individual genes are likely to determine the extent of ivermectin response in different parasite populations. Furthermore, we propose that genetic drift rather than genetic selection of SOR is the underlying driver of population differentiation, which has significant implications for the emergence and potential spread of SOR within and between these parasite populations.

Author summary

Onchocerciasis is a human parasitic disease endemic across large areas of Sub-Saharan Africa, where more than 99% of the estimated 100 million people globally at-risk live. The microfilarial stage of *Onchocerca volvulus* causes pathologies ranging from mild itching to visual impairment and ultimately, irreversible blindness. Mass administration of ivermectin kills microfilariae and has an anti-fecundity effect on adult worms by temporarily inhibiting the development *in utero* and/or release into the skin of new microfilariae, thereby reducing morbidity and transmission. Phenotypic and genetic changes in some parasite populations that have undergone multiple ivermectin treatments in Cameroon and Ghana have raised concern that sub-optimal response to ivermectin's anti-fecundity effect may increase in frequency, reducing the impact of ivermectin-based control measures. We used next generation sequencing of small pools of parasites to define genome-wide genetic differences between phenotypically characterised good and sub-optimal responder parasites from Cameroon and Ghana, and identified multiple regions of the genome that differentiated the response types. These regions were largely different between parasites from these two countries but revealed common molecular pathways that might be involved in determining the extent of response to ivermectin's anti-fecundity effect. These data reveal a more complex than previously described pattern of genetic diversity among *O. volvulus* populations that differ in their geography and response to ivermectin treatment.

Introduction

Onchocerca volvulus is a filarial nematode pathogen responsible for causing human onchocerciasis. The infection is associated with significant morbidity, ranging from itching to severe dermatitis and from visual impairment to blindness. This morbidity and its economic impact

have motivated large-scale disease control programmes in the foci located in South and Central America, Yemen and throughout Sub-Saharan Africa, where more than 99% of the global at-risk population, estimated at 100 million people, live. Currently, onchocerciasis control is based primarily on annual community directed treatment with the macrocyclic lactone, ivermectin (CDTI).

Ivermectin has a least two effects on the parasites: (i) an acute microfilaricidal effect that results in the rapid and almost complete removal of microfilariae—the larval progeny of adult worms—from the skin within days to weeks after treatment, and (ii) a sustained anti-fecundity effect that results in prolonged but temporary inhibition of the release of new microfilariae from adult female worms into the skin for approximately three to six months [1]. Although some reports describe an increased proportion of adult dead worms following multiple ivermectin treatment rounds [2, 3], ivermectin is generally considered not to be a macrofilaricide [4, 5]. Ivermectin mass treatment therefore aims to: (i) prevent, and to the extent possible revert pathology by removing microfilariae from the skin and eyes and delaying repopulation of these tissues with new microfilariae, and (ii) reduce transmission of *O. volvulus* by reducing the number of microfilariae that can be ingested by the blackfly (*Simulium*) vectors. Biannual (6-monthly) mass administration of ivermectin in hypo- and meso-endemic areas, and three-monthly ivermectin administration in hyperendemic areas of Central and South America have or are likely to have permanently eliminated transmission in most foci of the Americas [6–12]. Annual CDTI (expanded to biannual CDTI in some cases) and/or vector control have or are likely to have also eliminated onchocerciasis in a number of endemic areas in Africa [13–19]. The World Health Organization Roadmap on Neglected Tropical Diseases has set the ambitious target of achieving onchocerciasis elimination where feasible in Africa by 2020 [20], and the African Programme for Onchocerciasis Control proposed expanding this goal to 80% of the countries by 2025 [21].

In some areas of Africa, however, persistent microfilaridermia (microfilariae in the skin) and transmission have been reported after 15–20 years of ivermectin treatment [22–33]. In 2004, *O. volvulus* were identified in Ghana that exhibited an ivermectin response phenotype termed sub-optimal response (SOR). These SOR parasites were characterised by the presence of live stretched microfilariae in the uteri of the adult worms 90 days after treatment, and were associated with repopulation of the skin with microfilariae earlier/more extensively than expected based on prior data. Ivermectin exposure was found not to be an explanatory factor [29, 30]. Additional investigations have reported this phenotype in other areas in Ghana [27, 34, 35] and in Cameroon [36, 37]. Allele frequency change in a number of candidate ivermectin response genes (chosen for analysis based on specific hypotheses concerning mechanisms of resistance to the acute effects of ivermectin in *O. volvulus*) has also been demonstrated in these populations when sampled before and after several rounds of ivermectin treatment [38–44], which is consistent with population genetic changes associated with drug selection pressure. While genetic selection for SOR was not demonstrated, these studies suggest that these populations are being influenced at the genetic level by ivermectin treatment and, if these candidate genes mediate the phenotypic changes in ivermectin response, that SOR has a genetic basis that may involve selection on several genes.

The reproduction biology and transmission dynamics of the parasite after ivermectin treatment have been described [5, 36, 37, 45]. However, further work is required to understand: (i) the variability in response to ivermectin that has been observed in ivermectin-naïve parasite populations [46–48], (ii) the biological mechanism(s) by which parasites may tolerate and/or actively mitigate the inhibitory effects of ivermectin, and (iii) the corresponding genetic architecture underpinning these biological mechanisms, the influence of genetic selection, and the potential for SOR genotypes to be transmitted preferentially within and between parasite

populations and thus increase in frequency. Although there has been some debate regarding the existence of SOR to ivermectin in *O. volvulus* [49–53], modelling of SOR—using individual-patient data on the rate of skin repopulation by microfilariae following treatment in communities with different histories of control [27, 54]—has provided support for the conclusion that the early reappearance of microfilariae in the skin that defines SOR is most likely due to a decreased susceptibility of the parasite to ivermectin’s anti-fecundity effect. Onchocerciasis morbidity reduction is driven primarily by ivermectin’s microfilaricidal effect but its anti-fecundity effect, delaying repopulation of the skin with microfilariae, also contributes. More importantly, since both of these effects are critical for achieving interruption of parasite transmission, an increase in the frequency of SORs could jeopardise onchocerciasis elimination goals [55].

Genome-wide approaches are increasingly being employed to investigate the effects of drug selection in human pathogens, including but not limited to, *Plasmodium falciparum* [56–60], *Schistosoma mansoni* [61], *Leishmania donovani* [62] and *Salmonella enterica* Typhi [63]. Such approaches have been instrumental in both confirming known and identifying novel drug resistance-conferring loci in experimental and natural populations, and in clarifying the roles played by selection, parasite transmission and genetic drift in drug responses. An important feature of these studies is that they do not rely on assumptions concerning mechanisms of resistance or candidate resistance genes. The unbiased whole-genome approach has proven particularly useful where there is a plausible hypothesis of polygenic inheritance of a quantitative trait (QT, i.e. a trait that is determined by interactions between multiple genes and the environment, and therefore will have a continuous distribution of phenotypic values in a population) and when the analysis is based on natural, outbreeding field populations in a non-model species in which the population genetic structure is unknown but may confound simple candidate gene analysis. Given that a number of different candidate genes have been proposed to be associated with genetic response to ivermectin treatment in *O. volvulus* and other parasitic nematode species (see reviews from Gilleard [64] and Kotze *et al.* [65] for discussion of success and limitations of candidate gene approaches), the hypothesis that variation in response by the parasite to ivermectin is a polygenic QT is both plausible and likely. Analyses to understand SOR have been limited by several factors: *O. volvulus* is genetically diverse [66], populations are likely to be genetically structured at an unknown spatial scale [67, 68], and the parasite is a non-model outbreeding organism that is not amenable to more direct controlled genetic crosses and quantitative trait loci (QTL) mapping methods. These challenges are further exacerbated by limitations in providing an accurate estimate of the degree of SOR in a given individual or population; microfilarial density in the skin determined by skin snip is an indirect estimate of SOR and is not precise, especially when the parasite density in the skin is low due to ivermectin treatment [69], and analysis of the reproductive status of adult worms by embryogram is typically (but not exclusively) qualitatively measured although it is a QT. However, recent advances in our understanding of the genome [70] and transcriptome/proteome of *O. volvulus* [71], and more broadly, investment in publicly available helminth biology resources such as WormBase Parasite (<http://parasite.wormbase.org/>, [72]), have provided the means by which a genome-wide evaluation of ivermectin-mediated selection of drug response in *O. volvulus* may now take place.

In this study, we present a genome-wide genetic analysis of drug response by comparing genetic diversity within and between pools of adult *O. volvulus* from Cameroon and Ghana that have been classified as ivermectin-naïve or little treated [NLT]), good responder (GR), and ivermectin SOR based on host population and/or individual host treatment history, microfilarial repopulation in the host skin after ivermectin treatment and embryogram analysis of female worms. This analysis has provided new insight into the putative genetic and

biological mechanism(s) of response by *O. volvulus* to ivermectin. Underlying population structure, low susceptibility to ivermectin's anti-fecundity effect, and potential for increase in the frequency of such phenotypes are discussed in the context of efforts to control and eliminate onchocerciasis in Africa.

Materials & methods

Ethics statement

O. volvulus samples used in this study were acquired from previously described studies conducted in Cameroon [2, 36, 37] and Ghana [34, 35]. In those studies, the objectives and schedule of the study were explained to all eligible individuals, and those who agreed to participate signed a consent form and kept a copy of the latter. The data was de-identified prior to analysis. Ethical clearances were obtained for the original sampling of parasites from the National Ethics Committee of Cameroon (041/CNE/MP/06), the Cameroon Ministry of Public Health (D30-65/NHA/MINSANTE/SG/DROS/CRC and D31/L/MSP/SG/DMPR/DAMPR/SDE/SLE), the Ethics Committee of Noguchi Memorial Institute for Medical Research, (NMIM-R-IRB CPN 006/01-04) and McGill University (FWA 00004545).

Sample history and phenotyping of ivermectin response

Two separate experiments using adult female worms collected from people with known individual and/or community ivermectin treatment history and response phenotype are reported here. Phenotypic classification of ivermectin response has been described in detail [34–37], and for the present study was determined based on a combination of host level (skin microfilarial density) and female worm level (presence or absence of stretched microfilariae *in utero*) characteristics (Table A in S1 Text). The number of worms collected per host and phenotypically defined by embryogram from the original studies that describe the collection of samples are presented in Tables B–E in S1 Text.

The spatial distribution of sampling sites from the original studies is presented in Fig 1, which shows three maps: the first presenting the relative location and distance between Cameroon and Ghana in Africa, which are approximately ~1,370 km apart (to the mid-point of all sampling sites within each country) (Fig 1A), and the second and third maps showing sampling locations within Cameroon and Ghana, respectively; the sampling sites in Ghana span approximately ~215 km (Fig 1B) and in Cameroon, ~140 km (Fig 1C).

A total of 108 adult female parasites were used in the Pool-seq analyses; a description of the samples used, phenotypic characterisation, host and host-community ivermectin treatment history is presented in Table F in S1 Text. Briefly, Pool-seq samples from Cameroon consisted of 3 pools of parasites composed of: (i) ~40 drug-naïve or little treated (NLT) female worms from the Nkam valley, (ii) 22 ivermectin GR worms, and (iii) 16 SOR worms. The Cameroon GR and SOR parasites were collected from people living in the Mbam valley who live in communities that have participated in mass ivermectin administration since 1994 (at least 13 years prior to sampling). In addition to these treatments, these people from which parasites were collected also received between 4 to 13 doses of ivermectin between 1994 and 1997 in a controlled clinical trial [2]. Similarly, the Pool-seq samples from Ghana consisted of 3 pools of parasites made up from: (i) 10 worms categorised as NLT, having been exposed to ivermectin 455 and 90 days prior to the time of sampling, (ii) 7 GR worms exposed to 11–16 annual doses of ivermectin prior to sampling, and (iii) 13 SOR worms who had been exposed to 9–16 annual doses of ivermectin.

A total of 592 adult female worms were used in the single worm genotyping experiments; a summary of the worms selected for Sequenom genotyping as well as the treatment history of




Fig 1. Maps of sampling sites in Ghana and Cameroon. (A) Location of Ghana and Cameroon and distance between sampling sites. (B) and (C) sampling sites in Ghana (blue) and Cameroon (red), respectively. Both maps have been scaled to allow comparison of distance within and between sampling regions of each country. Numbers represent sampling locations as described in Table H in S1 Text.

<https://doi.org/10.1371/journal.pntd.0005816.g001>

the hosts and the area in which the hosts live are described in Table G in S1 Text. Parasites from Cameroon ($n = 436$) are categorised into three groups of samples: (i) parasites from the Nkam valley (NKA07; $n = 140$), from individuals who had been exposed to only a single ivermectin treatment 80 days prior to sampling, i.e., considered NLT [37], (ii) parasites from the

Mbam valley (MBM07; $n = 112$), from people who had been exposed to multiple rounds of ivermectin treatment prior to sampling as described above [37], and (iii) parasites from individuals in the Mbam valley who were truly ivermectin naïve (MBM94; $n = 184$), sampled in 1994 prior to introduction of CDTI [2]. Response phenotype data were not collected for the MBM94 parasites. In total, 184 ivermectin-naïve (with unknown phenotype), 225 GR, and 27 SOR parasites were genotyped. Worms from Ghana ($n = 156$) used for Sequenom genotyping were sampled from 6 communities with different ivermectin exposure histories (range: 2–17 treatments; **Table G in S1 Text**), and were composed of 105 GR and 43 SOR parasites. An additional 8 parasites that had been exposed to multiple annual ivermectin treatments but whose phenotype is not available were also included.

DNA preparation and genome resequencing

DNA extraction from worms from Cameroon was performed in the REFOTDE laboratory in Cameroon using an EZNA tissue DNA kit (Omega Bio-Tek Inc., Norcross, GA, USA). DNA extraction from worms from Ghana was performed using the DNeasy Blood and Tissue kit (Qiagen, Toronto, ON, Canada) at McGill University in Montreal, Canada.

The sequence data were generated from pools of worm DNA that were prepared by combining the DNA of individual worms that shared drug phenotype and geographic origin (i.e. NLT, GR or SOR from Ghana in 3 pools; NLT, GR and SOR from Cameroon in 3 pools; **S1 Table**). DNA was pooled at McGill University and sequencing was carried out at the McGill University and Génome Québec Innovation Centre (Montreal, Canada) across 8 Illumina GAII lanes (Cameroon: GR and Ghana: SOR pools had sufficient DNA to allow two sequencing lanes to increase sequencing depth). Overall, ~270-million 76-bp single-end sequences were generated, resulting in an estimated 35.18-fold (standard deviation [SD] ± 13.30) unmapped coverage per pool (or ~0.65–4 fold per worm if equal amounts of DNA/worm are assumed).

Read mapping and variant calling

Reads from each pool were aligned to the draft genome sequence *O_volvulus_Cameroon_v3* (WormBase Parasite; [70]) using BWA-MEM [73], after which reads were realigned around putative indels and duplicate reads (a PCR artifact that may skew variant read frequencies; see supplement of [74] for details) were removed using GATK (v3.3–0) [75]. Approximately 70% of the raw data were mapped, resulting in an average mapped coverage of 24.47 ± 9.07 per pool. Three ‘pooled-sequencing’ aware variant calling approaches were used to analyse the pooled mapping data: CRISP [76], FreeBayes (using the *pooled-continuous* parameter) (<https://github.com/ekg/freebayes>) and PoPoolation2 [77] (**S2 Table**). To ensure that comparisons could be made between all sequencing pools, the raw sequence nucleotide polymorphism (SNP) data were filtered using the following criteria: (i) the mapped read depth across a variant site was at least 8 reads but not greater than 3 SD from the genome-wide mean read depth for the given pool; (ii) there was no evidence of significant strand bias between forward and reverse reads (criterion applied to minimise SNPs caused by alignment artifacts, see supplement of [74] for details); (iii) variants were bi-allelic SNPs, and (iv) variants associated with reads mapped to *Wolbachia* or mtDNA sequences were removed. The intersection of these three approaches post-filtering yielded 248,102 shared variable sites relative to the reference sequence.

Genome-wide analyses of differentiation

To perform the genome-wide analyses of genetic differentiation of the sequencing pools, we used only variants found in the intersection of the three Pool-seq-aware SNP calling

approaches described above for all following analyses. Given the statistical uncertainty associated with interpreting low coverage read frequencies for any given SNP locus, we focused on analyses of relative genetic diversity between groups by calculating F_{ST} in 10-kb sliding windows across the genome, and F_{ST} of gene features based on the *O. volvulus*_Cameroon_v3 genome build from WormBase Parasite (<http://parasite.wormbase.org/>; *onchocerca_volvulus*. PRJEB513.WBPS5.annotations). F_{ST} values for each defined genomic window for both the genome-wide and genic datasets (10 kb or whole gene, respectively) were generated using PoPoolation2 [77] *fst-sliding.pl* with the following parameters:—min-count 2,—min-coverage 8,—max-coverage 2%, with corresponding individual haploid pool sizes specified). Analyses of significance between different groups for individual SNPs were performed using Fisher's exact tests (PoPoolation2 *fisher-test.pl*) to explore shared variants present in both Ghana and Cameroon. Analyses of variant frequency were performed using the variant read frequency generated from the CRISP output.

One of the primary aims of this analysis was to define regions of the genome that differed significantly between phenotypic classes in each country, on the assumption that such region (s) of genetic differentiation would contain a locus or loci that contributed to the phenotypic difference between the pools analysed. We defined a genomic location as significant if it consisted of two or more adjacent 10-kb windows (from the F_{ST} sliding window analysis) in which the GR vs. SOR F_{ST} values were greater than 3 SDs from the genome-wide mean F_{ST} within a 50-kb window (unless otherwise stated).

Single worm genotyping by Sequenom MassARRAY

A subset of genome-wide SNPs (160 in total) were chosen to explore ivermectin association and population structure further by Sequenom genotyping of individual adult female worms phenotyped for ivermectin response. DNA from 592 individual female worms (described in **Table G in S1 Text**) was prepared for Sequenom MassARRAY genotyping (Sequenom, Inc., San Diego, CA, USA)[78]. Due to the DNA quantity requirements for Sequenom analysis (600 ng per sample), many individual worm DNA samples (401 of 436 samples from Cameroon, 96 of 156 samples from Ghana) required whole genome amplification to increase the DNA concentration. This was performed using the REPLI-g screening kit (Qiagen, Toronto, ON, Canada). DNA concentrations of all samples were quantified using Quant-iT Pico Green dsDNA Assay Kit (Life Technologies Inc, ON, Canada), before sending to the McGill University and Génome Québec Innovation Centre for genotyping.

Population- and ivermectin association analyses of individually-genotyped worms

Sequenom data were analysed using PLINK [79]. Raw data were filtered based on allele frequency (loci with <0.05 minor allele frequency were removed: PLINK—maf 0.05), genotype quality (samples with <80% assay success rate were removed: PLINK—mind 0.2; SNPs with <80% genotype call frequency were removed: PLINK—geno 0.2). Filtered Sequenom data (130 SNPs in 446 samples [**Table G in S1 Text**; sample numbers in analysis are indicated in parentheses]; 81.25% of total SNPs and 75.33% of total samples, respectively) were analysed by multidimensional scaling to assess geographic vs. phenotypic influence on genetic diversity. Hardy-Weinberg equilibrium (HWE) was analysed using the same filtering conditions described above (PLINK—hardy), using the—keep function to analyse samples from each country separately. Discriminant analysis of principal components (DAPC) and population assignment based on membership probabilities were performed using the R package *adegenet* [80].

Accession numbers

Sequence data are archived at the European Nucleotide Archive (ENA) under the study accession PRJEB17785.

Results and discussion

A genome-wide approach was used to detect genetic signatures associated with the sub-optimal responder (SOR) phenotype of *O. volvulus* when exposed to ivermectin. The criteria used to select good responder (GR) and SOR parasites for analysis were based on (deemed to be related) host and parasite characteristics [29, 30] (**Table A in S1 Text**): (i) at the host level, the number of microfilariae in the skin determined by diagnostic skin snips is >7% of the pre-treatment value in SOR around 3 months post treatment (80 or 90 days for the samples from Cameroon and Ghana, respectively), whereas microfilariae are largely undetectable in GR at this time, and (ii) at the parasite level, SOR macrofilariae contain stretched microfilariae (ready to be released) *in utero* around 3 months post treatment (80 or 90 days for the samples from Cameroon and Ghana, respectively), as determined by embryogram, while GR do not. An SOR parasite, therefore, causes earlier repopulation of the skin with microfilariae than a GR parasite due to an earlier resumption of microfilarial release after temporary inhibition of fecundity. Samples were chosen from parasite cohorts obtained from Cameroon [2, 36, 37] and Ghana [34, 35]. An analysis of these sample cohorts (**Tables B-E in S1 Text**) revealed that both GR and SOR adult *O. volvulus* were simultaneously present in an individual host, supporting prior conclusions that the extent of response is determined by parasite characteristics, rather than insufficient ivermectin exposure [30]. The ratio of GR:SOR adult *O. volvulus* is not necessarily representative of all adult worms in a host since only a fraction of *O. volvulus* in a host are present in palpable nodules amenable to excision [46, 81, 82], and those parasites in deep non-palpable nodules or worm bundles can contribute to the skin microfilarial levels measured, i.e. the host-level response classification. This is evident in the data from the study conducted in Ghana in which all palpable nodules had been excised and phenotyped (**Fig A in S1 Text**); some hosts classified as SOR contained only female worms with a GR phenotype, whereas from a few hosts classified as GR, only SOR adult worms were in palpable nodules.

Genome resequencing of pooled, phenotyped *O. volvulus* from Ghana and Cameroon

To investigate the genetic differences between GR and SOR adult *O. volvulus*, whole genome sequencing was performed on pools of adult female worms from Cameroon and Ghana that were classified as naïve or little treated [NTL], or multiply treated GR and SOR groups based on the prior ivermectin exposure of the hosts and/or community from whom they were collected, and the host and parasite level response to ivermectin as described above (see **Table F in S1 Text** for characteristics of the worm pools). We identified 248,102 variable positions that were shared among all groups and passed our stringent filtering criteria (**S2 Table**), at an average marker density of 1 variant per ~389-bp (of the 96,457,494-bp nuclear genome). This represented only 32.7% of the total putative variants identified using the three variant analysis pipelines, primarily as a result of the relatively relaxed variant calling parameters of PoPoolation2 (**S2 Table**; 34.4% of SNPs called by PoPoolation2 were unique to this tool under the conditions used compared to 2.6% and 6.2% of unique SNPs called by CRISP and FreeBayes, respectively) and in part due to the stochastic variation in allele detection in low sequence coverage Pool-seq data.

Pool-seq has been used to estimate population genetic diversity in a number of different species [77, 83–86] on the assumption that individual read frequencies at a variant site are a proxy for allele frequency. This approach relies on sampling sufficient reads at any given position to be confident in detecting the diversity present; the more reads sequenced at a position, the closer the read frequency is to the true allele frequency. Considering that approximately 24.47-fold mapped coverage per pool (range: 0.53–3.05-fold coverage per worm) was obtained overall, it is unlikely that any of the pools was sequenced at sufficient depth to sample each genome present. Analyses of variation in read frequency between pools at low sequence coverage for any given nucleotide variant should, therefore, be treated with caution as they are confounded by significant statistical variation in coverage per genome [87], and likely under-powered for detecting true allele frequency differentiation [88]. In addition to strict filtering of the variants (e.g. to remove putative variant sites that were not detected by all three variant callers in all pools), we have attempted to account for this uncertainty by focusing on genetic variation calculated from multiple SNPs, either in sliding windows across the genome or on whole genes, rather than on individual nucleotide variants, an approach which has been demonstrated to improve significantly the accuracy of estimates of diversity at low coverage [89]. A significant finding of this study was that genetic variation that differentiated GR and SOR pools was not randomly distributed but was strongly clustered in multiple discrete regions of genome. This observation establishes clearly, for the first time, both the genetic architecture and likely mode of selection of ivermectin response in *O. volvulus*, which is described in detail below.

Genome-wide genetic differentiation between ivermectin response phenotypes

The two important questions with respect to the evolution of SOR are (i) which locus or loci are under selection, and (ii) whether the same loci are under selection in different populations, i.e., whether variation that differentiated SOR and GR worms in Ghana also differentiated SOR and GR worms in Cameroon. Shared variation between diverse geographic regions that differentiated SOR from GR would provide candidate markers that may predict ivermectin response in previously uncharacterised populations, and thus form the basis for the development of a ubiquitously applicable tool for monitoring the relative frequency of SOR and GR before and during CDTI. Pairwise analyses of individual SNPs (p-values from Fisher's exact test; Fig 2A) and F_{ST} calculated from 10-kb windows (Fig 2B) derived from the Pool-seq analysis both revealed a higher degree of differentiation between SOR and GR pools from Cameroon than between SOR and GR from Ghana, i.e., there were more loci or regions above significance thresholds in the Cameroonian pools. This difference is likely to be due to the unequal sample size between the two countries (Cameroon = 22 GR and 16 SOR worms; Ghana = 7 GR and 13 SOR worms); a greater proportion of total genetic diversity will be present in the Cameroon dataset as more worms are present, however, at the same time, the sequencing depth per Cameroon genome is lower than for the Ghana samples, and hence, will increase the stochastic variation in the Cameroon variant frequency. Although many single SNP loci from each country showed significant variation between SOR and GR pools when each country was analysed independently, only a single intergenic SNP (OM1b_7179218) was significantly different between pools and common to both countries (Fig 2A; red dot) after a Bonferroni genome-wide correction (Fig 2A; dashed lines) was applied. Furthermore, only six 10-kb regions that showed significant deviation above a genome-wide mean F_{ST} threshold of +3 SDs between GR and SOR were shared between Ghana and Cameroon (Fig 2B; dashed lines; red dots; S3 Table). Relaxing the threshold to +2 SDs yielded 22 additional 10-kb regions




Fig 2. Analysis of shared genetic variation that differentiates ivermectin good responder (GR) from sub-optimally responding (SOR) *Onchocerca volvulus* adult worms in both the Cameroon and Ghana population samples. Genetic differentiation was measured using individual single nucleotide polymorphisms (SNPs) (Fisher's exact test; **A**) or 10-kb windows (F_{ST} ; **B**). Dotted lines represent statistical cutoff applying the Bonferroni correction for SNPs and genome-wide mean $F_{ST} + 3$ standard deviations (SDs) (Cam: 0.355; Gha: 0.255) for 10-kb windows. Orange dots highlight differentiation above genome-wide cutoffs that is shared by both groups. Orange dots represent additional shared differentiation at 2 SDs in the F_{ST} analysis (**B**). Manhattan plots of genome-wide F_{ST} describing spatial genetic differentiation between GR and SOR pools for both Cameroon (**C**) and Ghana (**D**). Each point represents F_{ST} calculated for a non-overlapping 10-kb window. Plots are coloured to differentiate the main genomic scaffolds from unplaced scaffolds and contigs. Dotted lines represent genome-wide mean $F_{ST} + 3$ SDs (dark grey; Cam: 0.355; Gha: 0.255) and $F_{ST} + 5$ SDs (light grey; Cam: 0.508; Gha: 0.351).

<https://doi.org/10.1371/journal.pntd.0005816.g002>

that were able to differentiate GR from SOR and were shared between countries (Fig 2B, orange dots; S3 Table). A total of 28 F_{ST} windows at $> +2$ SDs is only marginally more than the number of windows that is expected to exceed $+2$ SDs by chance alone ($0.05^2 \times 9893$ 10-kb loci = 24.73), and may in fact be inflated considering: (i) 11 of the 28 10-kb windows were immediately adjacent to at least one other 10-kb window in the genome and, therefore, are unlikely to all be segregating independently, and (ii) four of these 28 10-kb windows contained sequences associated with Pao retrotransposon peptidase- and integrase-related proteins and a further two windows contained ribosomal subunits (S3 Table). Given the multi-copy nature of these sequences, the high F_{ST} value for these 6 windows is likely to be a technical error associated with poor read mapping of multicopy sequences rather than true biological differentiation. These results suggest that, even at a reduced genome-wide level of significance threshold

(i.e., $> +2$ SDs), little genetic variation that discriminated GR from SOR parasites was shared between the two countries.

To investigate the distribution of genome-wide genetic variation between ivermectin response groups, we analysed the relative positions of SOR vs. GR 10 kb F_{ST} windows $> +3$ SD in the *O. volvulus* genome. A striking finding was that the 10-kb regions that provided the most genetic differentiation between SOR and GR were not randomly distributed but were found in discrete clusters (Fig 2C & 2D); we interpret these clusters of significantly differentiated 10-kb windows (defined as 2 or more adjacent 10-kb windows within a 50-kb window $> +3$ SDs from the genome-wide mean F_{ST} calculated separately for each country) as putative quantitative trait loci (QTLs). These QTLs are composed of a variable number of 10-kb windows and contain multiple genes. In total, 18 putative QTLs that mapped to well-assembled regions of the genome were found in the Cameroon data (Fig 2C; mean QTL size of 66,389 bp \pm 55,157 bp SD) and 14 putative QTLs in the Ghana data (Fig 2D; mean size of 102,143 bp \pm 95,690 bp SD), representing 1.2% and 1.5% of the ~96.4 Mb nuclear genome, respectively (S4 Table).

These data provide strong evidence that (i) the SOR phenotype is a polygenic quantitative trait (QT), (ii) the Ghana and Cameroon SOR populations were genetically distinct as indicated by the apparent lack of concordance between Ghana and Cameroon SOR QTLs, and (iii) the different putative QTLs may be under selection in these two geographically separated parasite populations as indicated by only a single putative QTL common to Ghana and Cameroon SOR worms. These observations suggest that soft (rather than hard) selection on pre-treatment genetic variation in the two parasite populations has acted on different loci in each country, and in turn, resulted in a different signature of selection in each country (for principles of hard vs. soft selection, see Section 2 in S1 Text, including characteristics of soft and hard selection [Fig. B and Table J in S1 Text], and a simple multilocus QTL model to illustrate the genetic outcome of soft selection [Table I in S1 Text]). Soft selection also implies that it may therefore be difficult to separate differences between Ghana and Cameroon SOR populations that are the result of selection from those that are the result of genetic drift. However, the pattern of genetic variation within each country (see below) is consistent with the conclusion that the differentiation between GR and SOR worms (within the same country) is associated with phenotypic differences in ivermectin response.

Analysis of between-country genetic variation, and genetic diversity between responder phenotypes and drug-naïve worms

To test more explicitly for population structure between the two countries and thus, better understand the extent to which the standing genetic variation (see Section 2 of S1 Text) in these populations may have been shaped by the combination of selection and genetic drift, we analysed genetic differentiation between and within the two countries across the three treatment history/response categories (i.e. NLT, GR and SOR). Correlation of genome-wide allele frequencies within and between countries demonstrated significantly higher shared variation within each country than between countries, where allele frequency correlation was low (Fig 3A). This supports the conclusion that there is significant genetic differentiation between the parasite populations in the two countries, and that any genetic signal associated with SOR that might have been common to both countries would likely be masked by the presence of significant population genetic structure. Somewhat unexpectedly, a comparison of allele frequency correlations between response groups within each country suggested that, for both Cameroon and Ghana, the NLT worms were genetically more similar to the SOR worms than to the GR worms (Fig 3A). A direct pairwise comparison of the three treatment history/




Fig 3. Analysis of genetic diversity between ivermectin responder phenotypes and drug-naïve (NLT) worms. (A) Spearman rank correlation analysis of variant read frequencies from 248,102 SNPs. Values within each square represent the correlation coefficient for each pairwise analysis. (B) Degree of shared variation determined by pairwise comparisons of F_{ST} between treatment and response groups, summarised from 9,893 10-kb windows throughout the genome. F_{ST} distributions were compared statistically using a two-sample Kolmogorov-Smirnov [KS] test. (C) Variant read frequency spectrum from treatment and response subgroups for Cameroon and Ghana. The variant read frequency was calculated at each of the 248,102 SNP positions, from which the proportion of total variants in 0.05 frequency bins is presented. (D) Analysis of invariant loci per group as a proportion of the total number of variants observed, defined as variant read frequencies < 0.05 (blue) and > 0.95 (red).

<https://doi.org/10.1371/journal.pntd.0005816.g003>

response categories within each country using genome-averaged F_{ST} values (calculated from 9,893 10-kb windows) was consistent with this observation: NLT vs. SOR F_{ST} genomic medians were significantly smaller (Cameroon: 0.059; Ghana: 0.068) than either NLT vs. GR medians (Cameroon: median = 0.095; two-sample Kolmogorov-Smirnov [KS] test: $D = 0.0438$, $p < 0.001$; Ghana: median = 0.110; KS $D = 0.575$, $p < 0.001$), or GR vs. SOR medians (Cameroon: median = 0.112, KS $D = 0.544$, $p < 0.001$; Ghana: median = 0.104, KS $D = 0.495$, $p < 0.001$) (Fig 3B). The closer relationship between NLT and SOR than between NLT and GR is particularly surprising for Cameroon when one considers that the NLT and GR/SOR populations are from geographically distinct areas, i.e., the sampling sites within the Nkam and Mbam valleys were >100 km apart in two distinct river basins separated by the Western High Plateau of Cameroon (see Fig 1 for map of sampling sites). However, seasonal dispersal of the local vector species, *Simulium squamosum*, has been observed in Cameroon over greater distances than the distance between the two sampling regions here [90], and therefore, further investigation on the extent of seasonal transmission between the two river basins is required. Although these pairwise comparisons demonstrate differential degrees of genetic relatedness between the phenotypically defined groups within each country, the degree of genetic differentiation, i.e., median F_{ST} range between 0.059–0.112 in Cameroon and 0.068–0.110 in Ghana, is moderate and likely to reflect some, but not complete, restriction on gene flow between groups due to differential transmission. Given that GR parasites in both countries show significantly greater differentiation to both SOR and NLT groups, these data are consistent with greater transmission restriction of GR parasites than SOR parasites.

The observation of higher genetic similarity between the NLT and SOR populations supports the hypothesis of soft selection for SOR because it suggests that selection for SOR from an ivermectin-naïve population led to relatively little genome-wide reduction in genetic variation. A characteristic prediction of soft as opposed to hard selection (see Section 2 of S1 Text) is that unlike hard selection, soft selection should not markedly reduce the genome-wide genetic diversity following selection. Since the SOR phenotype is associated with an early resumption of reproduction and, consequently, with the early availability of SOR offspring in the skin for vectors to ingest, ivermectin treatment is likely to interrupt the transmission of SOR genotypes for only a relatively short period of time between CDTI rounds compared to GR transmission interruption. If SOR alleles are already present on many different genetic backgrounds in the NLT starting population, this continued transmission of SOR genotypes under drug treatment will maintain genetic diversity in the SOR population, which is consistent with what we have observed in the present study.

The strong, genome-wide, between-country genetic differentiation in the NLT populations implies that the standing genetic variation from which SOR is selected varies significantly between Ghana and Cameroon, and explains why the genetic outcome of selection of SOR differs between countries (as shown by the lack of concordance between Ghana SOR and Cameroon SOR populations). The presence of strong population structure between Cameroon and Ghana is not unexpected. The *O. volvulus* lifecycle is characterised by significant population (and mostly density-dependent) bottlenecks at each transmission event: only a miniscule proportion of microfilariae under the skin of human hosts are ingested by blackflies, and very few resulting infective larvae are subsequently transmitted to humans and establish as adult worms [91]. Repeated bottlenecks increase the severity of genetic drift by strongly enhancing the stochastic processes that generate genetic diversity between populations, independent of drug treatment, suggesting that genetic drift had created genetic differentiation between different parasite populations before initiation of CDTI, and that subsequent soft selection of SOR genotypes from these genetically distinct populations has led to SOR populations that are genetically distinct despite their phenotypic similarity. In contrast, CDTI interrupts

transmission of GR genotypes for a longer period of time. If this reduces the proportion of GR worms that contributes to the next generation, it will lead to a loss of genetic diversity and an increase in genetic drift in subsequent GR populations relative to both the population before CDTI was initiated and the SOR population. This expectation is consistent with genetic change described in single-gene studies following treatment over time in *O. volvulus* [38–44].

To further investigate the impact of soft selection on GR and SOR genetic diversity, we estimated the genetic diversity within the pools of GR and SOR worms from each country in two complementary ways: (i) by calculating the variant read spectrum per pool (as a proxy for the allele frequency spectrum, Fig 3C), and (ii) from the relative proportion of invariant SNP loci, which we have defined as SNP loci with variant read frequencies <0.05 or >0.95 (Fig 3D). These complementary analyses provide insight into the degree of genetic variation present within each drug response parasite pool, and will detect loss of genetic diversity. The pool of GR worms from both countries were less diverse and had a greater proportion of invariant loci than the pools of SOR and NLT parasites, particularly in Cameroon, whereas the SOR and NLT parasites had similar levels of genetic diversity.

Comparisons of genetic diversity between the pools of NLT, GR and SOR parasites therefore support our hypothesis of soft selection for SOR, and explain both the relatively subtle signature of selection in the SOR parasites and the strong population structure observed between the SOR parasites from Cameroon and Ghana.

Characterisation of molecular pathways identified from genes within QTLs that differentiate ivermectin response

In light of evidence suggesting that genetically separated parasite populations contain different standing genetic variation before the introduction of CDTI, and thus that ivermectin-mediated soft selection may produce different genetic outcomes in SOR parasites between Cameroon and Ghana, it was of interest to compare genes within the putative QTLs identified in the SOR worms from Ghana and Cameroon. While we identified only a single putative QTL that was common to the SOR parasites from the two countries, the putative QTLs from each country contained genes encoding proteins that act in a limited number of molecular pathways. This implies that although different genes may be under selection in Ghana and Cameroon, there may be a common biological mechanism that confers SOR in both countries (see Table 1 for a summary of genes with common functional characteristics and/or shared pathways identified in the QTLs, and S5 Table for characterisation of all genes within each QTL).

The most prominent group of genes under the putative QTLs defined above were associated with neurotransmission (17 genes in 14 QTLs), which was encouraging considering that the primary target of ivermectin is a ligand-gated channel at neuromuscular junctions [92]. Given that the duration of the anti-fecundity effect of ivermectin distinguishes the GR and SOR phenotypes, the fact that nine of those genes (in eight QTLs) were associated with acetylcholine signalling is of particular interest because acetylcholine signalling plays an important role in the regulation of egg laying in *Caenorhabditis elegans*, and therefore, may be relevant to ivermectin's anti-fecundity effect in *O. volvulus*.

These genes include a number of ion channels (*Ovo-acc-1*, *Ovo-lgc-46*, *Ovo-lgc-47*), and components of acetylcholine synthesis (*Ovo-cha-1*), transport (*Ovo-unc-17*, *Ovo-aex-3*), and regulation (*Ovo-pha-2*, *Ovo-snb-1*, *Ovo-emc-6*, *Ovo-nrfl-1*). The *unc-17* and *cha-1* mutants in *C. elegans* exhibit hyperactive egg-laying phenotypes associated with defects in laying inhibition [93, 94], and acetylcholine activation of egg laying in *C. elegans* is regulated by neuropeptides, serotonin and glutamate [95]. Furthermore, acetylcholine receptors have recently been proposed to be involved in the development of the nervous system during embryo- and

Table 1. Summary of genes with shared functional characteristics / pathways from QTL peaks from Ghana and Cameroon ^{a,b}.

Country	Ivermectin-associated	Neurotransmission ^c	LIN-12/Notch signalling	Muscle assembly / myosin organisation	Lipid synthesis and storage / stress
Cameroon		<i>Ovo-emc-6</i> (4; ACh) <i>Ovo-cha-1</i> (9; ACh) <i>Ovo-unc-17</i> (9; ACh) <i>Ovo-stg-1</i> (10.1) <i>Ovo-aex-3</i> (10.1; ACh) <i>Ovo-nrfl-1</i> (16; ACh) <i>Ovo-ncx-5</i> (24) <i>Ovo-sca-1</i> (25) <i>Ovo-lgc-46</i> (27; ACh)	<i>Ovo-crb-1</i> (4)	<i>Ovo-mup-4</i> (25) <i>Ovo-mua-3</i> (25) <i>Ovo-sca-1</i> (25) <i>Ovo-mlc-5</i> (26)	<i>Ovo-acs-16</i> (3) <i>Ovo-obr-2</i> (4) <i>Ovo-math-46</i> (7) <i>Ovo-hsp-17</i> (22) <i>Ovo-mtd-15</i> (25) <i>Ovo-cuc-1</i> (25)
Ghana	<i>Ovo-inx-5</i> ^b (5) <i>Ovo-klp-11</i> ^b (13) <i>Ovo-unc-44</i> (14)	<i>Ovo-nud-1</i> (1) <i>Ovo-inx-5</i> (5) <i>Ovo-stg-1</i> (10.2) <i>Ovo-aex-3</i> (10.2; ACh) <i>Ovo-unc-31</i> (13) <i>Ovo-lgc-47</i> (17; ACh) <i>Ovo-kin-2</i> (17) <i>Ovo-unc-26</i> (19) <i>Ovo-acc-1</i> (21; ACh) <i>Ovo-snb-1</i> (23; ACh)	<i>Ovo-bre-5</i> (5) <i>Ovo-pen-2</i> (29)	<i>Ovo-unc-82</i> (21) <i>Ovo-nmy-1</i> (21)	<i>Ovo-hsb-1</i> (1) <i>Ovo-sms-1</i> (13) <i>Ovo-spl-1</i> (17) <i>Ovo-fat-4</i> (19) <i>Ovo-tat-2</i> (19)

^a Quantitative trait loci (QTL) identification is provided in parentheses (refer to [S4 Table](#) for a description of each QTL and [S5 Table](#) for the genes within).

^b putative ivermectin association as described in text

^c loci associated with acetylcholine neurotransmission are abbreviated with ACh.

<https://doi.org/10.1371/journal.pntd.0005816.t001>

spermatogenesis in the filarial parasite *Brugia malayi* [96]. In addition, two recent studies demonstrated inhibition of L-AChR receptors in *C. elegans* by ivermectin [97] and antagonistic effects of abamectin on nicotinic acetylcholine receptors [98], implying that under some circumstances ivermectin may act directly on acetylcholine signalling. We therefore hypothesise that modification of neurotransmission in general, and acetylcholine signalling pathways in particular, may contribute to ivermectin SOR and reflects an overall adjustment in neuromuscular signaling that mitigates the effects of ivermectin. This variation may also contribute to the changes in fecundity that have been associated with the SOR phenotype [99] by changing the way in which neurotransmission might influence the release of microfilariae in an analogous fashion to neuronal control of egg laying in *C. elegans*. Given the enrichment of neuronal genes that may play a role in regulating reproduction, it is of interest to note that the single QTL that is shared between Cameroon and Ghana SOR parasites includes *Ovo-aex-3*, a neuronal protein and regulator of synaptic transmission. This gene may be of particular interest because the *C. elegans* orthologue plays a role in reproduction and also in regulation of pharyngeal pumping [80] (a phenotype for which alleles have been associated with reduced sensitivity to ivermectin in *C. elegans*). In addition, this QTL also includes *Ovo-stg-1*, which may be of interest due to its putative chaperone-like role in regulating ionotropic glutamate receptor (iGluR) function and a hypothesised role in protecting neurons from excitotoxicity or inappropriate depolarisation in *C. elegans* [81].

Nine putative QTLs contained genes associated with stress responses, including heat-shock proteins (*Ovo-hsp-17*, *Ovo-hsb-1*), and genes required for the synthesis (*Ovo-acs-16*, *Ovo-fat-4*, *Ovo-spl-1*, *Ovo-tat-2*), regulation and storage (*Ovo-obr-2*, *Ovo-sms-1*, *Ovo-math-46*, *Ovo-mtd-15*, *Ovo-cuc-1*) of lipids. Variation in gene expression in lipid metabolism-encoding genes following ivermectin treatment in *C. elegans* has been described [100], which was interpreted as a

metabolic adaptation to starvation due to ivermectin inhibition of pharyngeal pumping but may also be a more general indicator of organismal stress. Genes associated in general with stress responses, including lipid metabolism, are often reported in genome-wide analyses for loci under drug selection pressure [56].

Other genes under the putative QTLs include those acting in pathways involved in developmental processes, including muscle assembly and myosin organisation (three QTLs contained 6 loci; *Ovo-mup-4*, *Ovo-mua-3*, *Ovo-mlc-5*, *Ovo-unc-82*, *Ovo-nmy-1*, *Ovo-sca-1*), and germline and larval development signals associated with notch signaling (three QTLs), specifically with the suppression (*Ovo-bre-5*) or cleavage (*Ovo-pen-2*, *Ovo-crb-1*) of the LIN-12 receptor. The relevance, if any, of these developmental genes to ivermectin response is not known.

This list of genes that fall under the QTLs leads to a hypothesis of SOR as tolerance to ivermectin's anti-fecundity effect brought about by a re-tuning of neuronal function in combination with a stress response. We acknowledge the tentative nature of this hypothesis given: (i) the limitations in the resolving power of genetic-association analysis based on modest sequencing depth of a limited number of pooled samples, that could result in both false-positives and a lack of power to detect rare variation, i.e., false-negatives, (ii) only a single comparison between GR and SOR parasites was made from each country, (iii) the inability to carry out more specific analysis of coding sequence variation imposed by limited genetic resolution, (iv) the large number of predicted genes that lack functional annotation in the *O. volvulus* genome (~67.4% of the coding sequences within the QTLs are unannotated or hypothetical), and (v) the methods available for phenotype classification, which has limited sensitivity for the determination of the presence and extent of microfilarial density in the skin [69] and is qualitative with respect to the presence or absence of live stretched microfilariae *in utero*, which in turn decreases the power of genetic association. However, the polygenic signature associated with ivermectin response is consistent with the outcome of two genome-wide scans examining ivermectin resistance in *Dirofilaria immitis* [101], and *Teladorsagia circumcincta* [102], both of which support the hypothesis that ivermectin response is a quantitative, multigenic trait. Moreover, the enrichment of neurotransmission and stress response genes in the QTLs that differentiate GR and SOR parasites in two geographically independent populations is striking, and does provide support for our hypothesis of a polygenic QT characterised by earlier recovery from the acute effects of ivermectin on fecundity.

If correct, this hypothesis implies that the SOR adult worms remain sensitive to the acute effects of ivermectin on fecundity but recover more quickly than GR worms. Early recovery from the acute effect of ivermectin on fecundity does not require a mechanism that is specific to the mode of action of that acute effect, so a polygenic retuning or buffering of the neuronal regulation of reproduction that leads to earlier recovery of fertility is biologically plausible. It may also explain why our analyses have failed to validate candidate genes that would protect worms against ivermectin's acute effects (see below).

Analysis of candidate ivermectin-resistance genes

Given the extensive literature focused on candidate genes (i.e. genes chosen for analysis based on specific hypotheses concerning mechanisms of resistance to the acute effects of ivermectin in *O. volvulus*) from *C. elegans* and other helminths for which ivermectin is used as an anthelmintic, and the apparent absence of these genes from the QTLs described here, it was important to investigate these genes, which included glutamate-gated chloride channels (*Ovo-avr-14*, *Ovo-glc-2*, *Ovo-avr-15*, *Ovo-glc-4*), p-glycoproteins (*Ovo-pgp-1*, *Ovo-pgp-10*, *Ovo-pgp-11*, *Ovo-plp-1*), ABC transporters (*Ovo-abc-1*, *Ovo-abc-2*, *Ovo-abc-3*) and other candidates (*Ovo-ben-1* [beta tubulin], *Ovo-lgc-37*, *Ovo-mrp-7*, *Ovo-dyf-7*). *Ovo-abc-1* was the only candidate gene

found in a QTL. For the majority of the other genes (including *Ovo-pgp-11* for which variation in allele frequency in a *pgp* orthologue of the closely related filarial parasite *D. immitis* has been demonstrated to correlate with loss of ivermectin efficacy [103]), no significant SOR vs. GR F_{ST} differences were observed (S6 Table). *Ovo-abcf-1* (in QTL-5), *Ovo-abce-1*, *Ovo-dyf-7*, and *Ovo-pgp-10* did show moderate levels of differentiation, but none were statistically significant. Given that our data suggest that parasite populations are structured and that alleles associated with ivermectin response may vary between populations, we cannot exclude that these loci contribute to variability in ivermectin susceptibility in other *O. volvulus* populations. However, considering the evidence of multiple putative QTLs and strong geographical population structure, it is possible that single candidate gene comparisons may have been confounded by population structure and the polygenic nature of the trait. We conclude that there was no evidence of significant genetic differentiation in these candidate genes between the SOR and GR populations compared here.

Three of the 31 putative QTLs did contain genes associated with neuronal function that have been linked previously to ivermectin sensitivity in *C. elegans* (Table 1; S5 Table): *Ovo-unc-44*, a likely orthologue of a *C. elegans* gene that influences ivermectin sensitivity and is involved in neuronal development [104], *Ovo-inx-5*, which in *C. elegans* encodes an innexin gap junction protein that is associated with the pharyngeal motor neurons and is related to *unc-9* (a known ivermectin-resistance allele [105]), and *Ovo-klp-11*, a kinesin motor protein found in the cilia of chemosensory neurons in *C. elegans*, which has significant homology to, and is a likely binding partner of, *Ovo-osm-3*, alleles of which have been described to decrease sensitivity to ivermectin in *C. elegans* [104].

Geographic and genetic distribution of ivermectin susceptibility

Given the importance of the distinction between population structure as a result of genetic drift and phenotypic differentiation as a result of selection for SOR, we sought to investigate ivermectin response genetics in a larger cohort of individual female worms (most having been characterised for their ivermectin response phenotypes via embryograms [34–37]; Table G in S1 Text) by genotyping individual worms at 160 SNP loci by Sequenom (S7 Table). The loci were chosen based on the original Pool-seq analyses to determine the degree of genetic association with response phenotype, and to characterise genetic structure within these populations. Multidimensional scaling analysis (MDS) was used to interrogate the Sequenom genotyping data from 446 female worms at 130 SNPs that passed filtering criteria. Three aspects of the data are highlighted (in different panels, Fig 4): (i) between-country population structure, (ii) within-country population structure, and (iii) differentiation between response phenotypes.

Consistent with the Pool-Seq analysis, we observed clear genetic differentiation between Sequenom-genotyped worms from Ghana and worms from Cameroon: there were very few [blue] Ghanaian worms mixed with the [red] Cameroon worms (Fig 4A), regardless of response phenotype. Analysis of worms by their community of origin to allow within- as well as between-country comparisons did not reveal any internal genetic structure in the Ghanaian populations or between the Cameroonian NKA07 and MBM07 [pink and red, respectively] populations (Fig 4B).

Interpretation of the Cameroon data is more complex than for Ghana due to the likely existence of underlying population structure that is both temporal and spatial in origin: within Cameroon, MBM94 [light orange] was genetically distinct from both NKA07 and MBM07 populations but NKA07 and MBM07 were indistinguishable. MBM94 and MBM07 are two samples drawn from the same geographical location in Cameroon (the Mbam valley) at different times: MBM94 was sampled in 1994 before ivermectin distribution began, and is drug-




Fig 4. Analysis of genetic differentiation among 446 *O. volvulus* female worms from Ghana and Cameroon individually genotyped at 130 loci distributed throughout the genome. Multi-dimensional scaling analysis was used to determine the relative genetic similarity between worms. Plots contain the same data, but have been presented to emphasise the degree of genetic differences between countries (A), sampling communities within each country (B), and their treatment exposure and phenotypic response to ivermectin if known (C). Ghanaian sampling sites: Asubende (ASU), Begbomdo (BEG), Jagbenbendo (JAG), Kyngakrom (KYG), New Longoro (NLG), and Wiae (WIA). Cameroonian sampling sites: Nkam valley (NKA07), Mbam valley sampled in 1994 (MBM94) before introduction of annual CDTI in 1994 and sampled in 2007 (MBM07).

<https://doi.org/10.1371/journal.pntd.0005816.g004>

naïve, whereas MBM07 was sampled in the Mbam valley after 13 years of annual CDTI and contains approximately 16% SOR and 84% GR parasites ($n = 112$). Given that MBM07 is still largely GR, we interpret this signal of strong population differentiation as the result of genetic drift from MBM94, i.e., of largely stochastic (rather than deterministic, i.e., selection) genetic change likely brought about by multiple population bottlenecks imposed by the impact of 13 years of ivermectin treatment on parasite transmission and hence on effective population size. If this interpretation is correct, the striking similarity between MBM07 and NKA07 is coincidental: genetic drift is a stochastic process, and previously distinct populations may become more similar by chance alone.

Alternatively, the similarity between NKA07 and MBM07 may indicate that there is transmission between NKA07 and MBM07, such that as ivermectin shrank the originally naïve MBM94 population over 13 years, exchange of parasites between the Nkam and the Mbam valleys mediated by vector or human migration brought these two initially dissimilar populations closer together genetically. While the Nkam valley had not received CDTI at the time the NKA07 samples were collected (the samples genotyped are classified as NLT, having only been exposed to a single experimentally controlled round of ivermectin treatment [37]), some communities in the Nkam valley are only ~10 km from communities across the Nkam river which have received annual CDTI for >10 years. Consequently, the NKA07 parasites may not be entirely naïve. However, transmission of multiply-exposed parasites from these villages into NKA07 patients is unlikely to account for the similarities between NKA07 and MBM07, as the NKA07 population was largely composed of GR parasites (94.3%, $n = 140$).

Our data do not allow discrimination between these two hypotheses. In either case, the Cameroon data underline how little is known about the determinants of *O. volvulus* population structure in general, and the genetic impact of population bottlenecks imposed by ivermectin-mediated temporary interruption and long-term reduction of transmission in *O. volvulus*. These data also illustrate the confounding effect of underlying population structure on our ability to distinguish between selection and drift as drivers of genetic differentiation between two population samples, regardless of the origin of that structure, whether due to a drug-induced population bottleneck, natural drift over time, or parasite immigration from a drug-naïve into a drug-treated population.

Analysis of the distribution of response phenotypes revealed no clear separation of GR (green) from SOR (red) in either Ghana or Cameroon samples (Fig 4C). Careful comparison of Fig 4B and 4C (and reference to Table G in S1 Text) show that the Cameroon NKA07 parasite group in Fig 4B (pink dots) is composed almost entirely of GR worms (SOR frequency of approximately 5%, $n = 140$), whereas the MBM07 parasite group (Fig 4B, red dots) is composed of a mix of GR worms (Fig 4C, green dots) and SOR worms (Fig 4C, red dots; SOR frequency approximately 16% [$n = 112$]), but that the GR and SOR worms in both NKA07 and MBM07 are intermingled, i.e. the differentiation between (NKA07 + MBM07) and MBM94 in Fig 4B is unrelated to the distribution of drug phenotypes in Fig 4C. Thus, these data suggest that genetic differentiation between the Cameroon populations is not correlated with response phenotype.

To characterise further the differences between GR and SOR parasites within each country, we analysed genotype frequencies for Hardy-Weinberg equilibrium (HWE). A greater number of SNPs were significantly out of equilibrium in the GR populations compared to the SOR populations from both countries (significance threshold of $p < 0.05$; 111 vs. 20 (of 131) SNPs in the Cameroon GR vs. SOR parasites, S8 Table; and 80 vs. 68 (of 121) SNPs in the Ghana GR vs. SOR parasites, S9 Table). In this respect, the Sequenom genotype and the whole genome PoolSeq data are concordant: greater deviation from HWE in the GR populations is best explained by ivermectin treatment reducing effective population size and genetic diversity and

increasing genetic drift in the GR worms, but not in the SOR worms or ivermectin-naïve populations.

Collectively, these Sequenom data suggest that spatial (between Ghana and Cameroon) and temporal (pre- and post-13 years of drug exposure within Cameroon) genetic differentiation was readily detectable by genotyping at these 130 SNP loci, but that this genotyping failed to detect the relatively weaker signal of genetic differentiation between GR and SOR phenotypes. This is illustrated most clearly by comparison of the Ghanaian and Cameroon SOR populations (Fig 4C), where the MDS coordinates of Ghanaian SOR individuals cluster with the Ghanaian GR individuals, and Cameroon SOR individuals cluster with Cameroon GR, evidence that SOR alleles exist in genetic backgrounds determined by their population of origin, and that the genetic signature of soft selection for SOR in different naïve populations is weak compared to the pre-existing population structure that is the product of genetic drift. This is further supported by an analysis of genotype-based assignment of individual parasites to their respective populations (Table K and Fig C of S1 Text). Greater than 99.5% of individuals were correctly assigned to their country of origin by their genotype, and between 40–92.4% of individuals from Cameroon and 0–97% of individuals from Ghana to their respective communities or regions. In contrast, 0% of Cameroon worms and only 8.1% of Ghanaian worms were correctly assigned as SOR worms on the basis of their genotypes, i.e., there is strong correlation between Sequenom genotype and place of origin but little or no correlation between Sequenom genotype and ivermectin response phenotype. Furthermore, the MDS analysis of the three Cameroon groups of samples (Fig 4C) supports the view that not only do past histories of geographical or ecological separation result in genetic drift and hence differentiation between *O. volvulus* populations, but that reduction or interruption of transmission and reduction in population size by ivermectin treatment, and/or migration from untreated into treated populations also drives drift and masks selection.

Implications for control and elimination

The success of CDTI in the majority of areas in Africa where CDTI has been implemented with good coverage [17], suggests that the alleles responsible for SOR are not common across Africa and that CDTI can interrupt transmission in many populations. This success is clearly dependent on epidemiological and programmatic factors such as the intensity of blackfly biting on humans and the frequency and achieved coverage of and adherence to CDTI [28, 33, 106–108]. However, it is also clear that drug response by *O. volvulus* is not uniform in all ivermectin-naïve populations [5, 27, 37, 46, 47], and that in some naïve populations (such as those sampled here), parasites with sub-optimal response to ivermectin's anti-fecundity effect are present prior to ivermectin treatment. The data presented here provide an explanation for the presence of SOR worms in ivermectin-naïve populations, and support the view that SOR to ivermectin in those populations is a genetically determined trait that can increase in frequency as a result of selection. Selection for SOR has progressed to an extent in the populations sampled for analysis here, as the genetic signal of that selection can be detected in the Pool-seq data. The genetic signal is, however, weak because it is based on soft selection acting on many genes that contribute to a QT. The implications of these conclusions for control and elimination hinge on three crucial questions.

The first question is whether, and under what circumstances, SOR can be detected genetically. The whole genome Pool-seq data demonstrate that it is possible to detect SOR genotypes in an analysis of 248,102 SNPs but our first attempt to validate SOR alleles in individual worms by reducing the number of SNPs to a panel 130 SNPs in Sequenom genotyping failed. This failure is likely due to soft selection for SOR leaving a faint genetic signature in the SOR

populations compared to the very strong, pre-existing population structure signals and probable ivermectin-induced genetic drift in treated populations. More careful marker selection based on better quality whole genome sequence data from individual- rather than pooled-worms may solve this problem and permit sensitive detection of SOR genotypes in samples drawn from a single parasite population, i.e., transmission zone.

The second crucial question is whether it is possible to predict the likelihood that SOR frequency will increase to a level that prevents elimination of *O. volvulus* transmission in a given population. Our data suggest that ivermectin reduces the population size of GR worms, as one would expect, but that the population of SOR worms is stable and/or increasing as the GR population shrinks. In very simple terms it is, therefore, a race: will the rate of population contraction (driven by the temporary interruption and long-term reduction of transmission of GR worms) outpace the rate at which the SOR population stabilises and expands (because they continue to be transmitted). If GR decline is faster than SOR expansion and the parasite population declines below the transmission breakpoint, local elimination will occur. If expansion of the SOR population prevents the parasite population declining below that threshold, transmission will persist, prevalence of infection will rebound and elimination will not occur. The outcome of the race will be determined by: (i) the starting frequency of SOR in a naïve population when ivermectin treatment begins, (ii) the relative rates of GR population contraction and SOR population expansion, and (iii) the population size at which transmission is no longer sustainable (the threshold for maintenance of transmission or transmission breakpoint). Developing genotyping assays that can measure the pre-treatment (or current) SOR frequency and monitor the relative rates of GR contraction and SOR stabilisation/expansion (the two critical parameters identified above) in populations undergoing CDTI is therefore essential to detect populations in which elimination may prove problematic. Furthermore, the response phenotypes in terms of the dynamics of microfilarial production and reappearance in the skin [36], and thus availability of skin microfilariae for vectors to ingest need to be better understood. They could then be taken into account for timing CDTI relative to vector abundance so that the ratio of progeny of SOR/progeny of GR is minimal when the availability of vectors is maximal.

The third crucial question is whether SOR is likely to spread from one location to another. The analysis of population structure suggests that all of the communities sampled in Ghana are in a single transmission zone (there is no internal population structure between the Ghanaian communities), so that SOR could be transmitted between communities in this region of Ghana. This is also likely to be true for the regions sampled in Cameroon. The tentative conclusion from analysis of the Sequenom data for MBM94, MBM07 and NKA07 from Cameroon suggests that immigration from an area not under CDTI (Nkam valley) into a population under CDTI may occur (suggested by the similarity between MBM07 and NKA07), even if the pre-treatment level of transmission between the two populations is low (as is suggested by comparison of NKA07 and MBM94, which are genetically distinct populations). While the concept of recrudescence in areas undergoing control as a result of immigration from neighbouring regions with less or no control is not new, these data provide the first genetic evidence that such immigration has likely occurred. In contrast, Ghana and Cameroon are clearly separated genetically, which implies there is no transmission of *O. volvulus* at this scale and SOR will not spread from Ghana to Cameroon (or *vice versa*). While this is not surprising given the location and distance between the two countries; the data show that genetic markers were able to detect transmission between endemic areas within Cameroon and Ghana (i.e. are transmission zone markers) and thus could be a useful tool for onchocerciasis control programmes. Such a tool could support decisions on whether to stop CDTI when criteria for stopping CDTI have been met in one area but not in others in a geographical context that makes transmission

between these two areas possible. These data also suggest that not only can genetic markers sensitively detect transmission between geographic locations, but also that QLTs associated with SOR could increase in frequency in neighbouring regions having little drug selection pressure as a result of transmission.

With respect to SORs, genotyping assays will benefit control programmes in multiple ways by (i) providing diagnostic tools to monitor changes in the frequency of SORs (non-invasive through genotyping infective larvae in the vector [109]), (ii) discriminating between genetic explanations for persistence of transmission (i.e., presence/selection for SOR) and other factors that determine CDTI success (such as host-related factors, treatment coverage and compliance, pre-control prevalence and intensity of infection and vector biting rates [48–53, 107]), (iii) suggesting a trigger for the initiation of alternative treatment strategies, such as anti-*Wolbachia* treatment [110, 111], local vector control, new treatments that may become available such as moxidectin [46, 112], combinations of interventions, or novel macrofilaricides (as reviewed in [113]) in populations where persistent transmission is observed despite prolonged CDTI [114].

Conclusions

The data presented suggest that the evolution of SOR to ivermectin in *O. volvulus* is via soft selective sweeps of pre-existing QTLs rather than via a hard selective sweep of a relatively rare resistance-conferring mutation. The outcome of this soft selection is the accumulation of many alleles in a limited number of functional pathways that facilitate the recovery of adult female worm fecundity from the inhibitory effects of ivermectin. This is consistent with the observation that the acute microfilaricidal and macrofilarial anti-fecundity effects of ivermectin remain unaltered in SOR populations, but that the difference between SOR and GR parasites is quantitative variation in the rate and extent to which microfilarial production is resumed after ivermectin treatment. This conclusion (of a soft selective sweep of quantitative variation in the rate of recovery from the effects of ivermectin) is based on the presence of multiple, geographically independent genetic signals throughout the genome that differentiate GR and SOR pools and the apparent preservation of genetic diversity within the SOR populations following selection. Furthermore, when these data are considered together with the population bottlenecks that characterise the transmission of *O. volvulus* through its lifecycle and the likelihood of some degree of inbreeding, we conclude that *O. volvulus* populations are variable and can be structured due to allele frequency change in the absence of selection, i.e., as a consequence of genetic drift. What is unclear is the extent to which each putative QTL contributes to the development of SOR. The failure of the single worm genotyping using a panel of 130 SNPs to define more precisely a region of the genome associated with SOR does suggest that the signature of selection in these populations is subtle and that no single putative QTL dominates the response; further validation of the putative QTLs is clearly required. A more thorough association analysis of each genomic region with SOR may be achieved by additional whole genome sequencing using single adult worms (as opposed to pool sequencing as described here) together with a more precise estimation of the ivermectin response of the individual worm. This would allow fine mapping of QTLs, and estimation of their effect size and penetrance, and ultimately, of the heritability of SOR. Such analyses should take transmission zones and population stratification into account to determine the extent of gene flow and therefore, the ability of SOR alleles to be transmitted within and between populations. Additional sequencing of individual parasites may also provide greater confidence in assigning genetic associations to individual SNPs, opening the way to investigation of the likely function of individual SNPs as putative SOR-conferring variants. Given the increasing accessibility of

genomic resources, the reduced cost of next-generation sequencing, and the ability to look at the whole genome in an unbiased way, we propose that genome-wide analyses such as those applied here should replace candidate gene approaches for future work concerned with the genetics and diagnosis of drug resistance in helminth parasites.

Supporting information

S1 Table. Sequencing library composition, sequencing data and mapping statistics.
(XLSX)

S2 Table. SNP calling statistics derived from CRISP, FreeBayes and PoPoolation2 Pool-seq variant analysis, highlighting total SNPs called and the intersection between different SNP callers.
(XLSX)

S3 Table. Analysis of shared regions of genetic differentiation between SOR and GR of both Cameroon and Ghana. Table provides details of variants presented in [Fig 2A and 2B](#) of the main manuscript.
(XLSX)

S4 Table. Characterisation of QTL clusters that differentiate SOR and GR in either Cameroon or Ghana. Table provides details of regions of differentiation presented in [Fig 2C and 2D](#) of the main manuscript.
(XLSX)

S5 Table. Characterisation of genes within QTL clusters that differentiate SOR and GR in either Cameroon or Ghana.
(XLSX)

S6 Table. Analysis of genetic differentiation between GR and SOR pools in ivermectin-resistance associated genes from the literature and in clusters.
(XLSX)

S7 Table. Names and coordinates of the 160 SNPs genotyped by Sequenom.
(XLSX)

S8 Table. HWE analysis of GR and SOR populations from Cameroon.
(XLSX)

S9 Table. HWE analysis of GR and SOR populations from Ghana.
(XLSX)

S1 Text. Supporting information. Extended information regarding sample history and response phenotype (Section 1). Extended discussion of hard- and soft-selective sweeps (Section 2). Population assignment based on Sequenom genotyping of individual worms (Section 3).
(PDF)

Acknowledgments

We would like to thank all of the patients and collaborators from Cameroon and Ghana who participated in the studies, as well as the Ministry of Public Health from Cameroon and the Ministry of Health from Ghana. We would like to acknowledge Pierre Lepage, Rosalie Frechette, Audrey Ann Kustec, Patrice Charbonneau-Larose and Valérie Catudal from the Genome Quebec Innovation Centre, Andrew Robinson and Nathan Hall from La Trobe

University for computational support, James Cotton (Wellcome Trust Sanger Institute) and Shannon Hedtke (La Trobe University) for critical reading of the manuscript, and Matthew Berriman and James Cotton (Wellcome Trust Sanger Institute) for pre-publication access to *O. volvulus* genomic resources.

Author Contributions

Conceptualization: Catherine Bourguinat, Michel Boussinesq, Roger K. Prichard, Warwick N. Grant.

Data curation: Stephen R. Doyle, Catherine Bourguinat, Annette C. Kuesel, Mike Y. Osei-Atweneboana, Michel Boussinesq.

Formal analysis: Stephen R. Doyle.

Funding acquisition: Stephen R. Doyle, Catherine Bourguinat, Sébastien D. S. Pion, Joseph Kamgno, Samuel Wanji, Martin Walker, Maria-Gloria Basáñez, Daniel A. Boakye, Mike Y. Osei-Atweneboana, Michel Boussinesq, Roger K. Prichard, Warwick N. Grant.

Investigation: Stephen R. Doyle, Catherine Bourguinat, Hugues C. Nana-Djeunga, Jonas A. Kengne-Ouafo, Sébastien D. S. Pion, Jean Bopda, Joseph Kamgno, Samuel Wanji, Hua Che, Annette C. Kuesel, Martin Walker, Maria-Gloria Basáñez, Daniel A. Boakye, Mike Y. Osei-Atweneboana, Michel Boussinesq, Roger K. Prichard, Warwick N. Grant.

Project administration: Annette C. Kuesel, Roger K. Prichard, Warwick N. Grant.

Resources: Sébastien D. S. Pion, Samuel Wanji, Mike Y. Osei-Atweneboana, Michel Boussinesq, Roger K. Prichard.

Software: Stephen R. Doyle.

Visualization: Stephen R. Doyle, Warwick N. Grant.

Writing – original draft: Stephen R. Doyle, Warwick N. Grant.

Writing – review & editing: Stephen R. Doyle, Catherine Bourguinat, Hugues C. Nana-Djeunga, Jonas A. Kengne-Ouafo, Sébastien D. S. Pion, Jean Bopda, Joseph Kamgno, Samuel Wanji, Hua Che, Annette C. Kuesel, Martin Walker, Maria-Gloria Basáñez, Daniel A. Boakye, Mike Y. Osei-Atweneboana, Michel Boussinesq, Roger K. Prichard, Warwick N. Grant.

References

1. Remme JHF, Boatín B, Boussinesq M. Helminthic Diseases: Onchocerciasis and Loiasis. In: SR Q, WC C, editors. The International Encyclopedia of Public Health. Vol. 3. 2nd ed. Oxford: Elsevier; 2016. p. 576–87.
2. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga N, Duke BO. Effects of standard and high doses of ivermectin on adult worms of *Onchocerca volvulus*: a randomised controlled trial. Lancet. 2002; 360(9328):203–10. [https://doi.org/10.1016/S0140-6736\(02\)09456-4](https://doi.org/10.1016/S0140-6736(02)09456-4) PMID: 12133654
3. Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B. Effects of multiple monthly doses of ivermectin on adult *Onchocerca volvulus*. Am J Trop Med Hyg. 1990; 43(6):657–64. PMID: 2267970
4. Kläger SL, Whitworth JA, Downham MD. Viability and fertility of adult *Onchocerca volvulus* after 6 years of treatment with ivermectin. Trop Med Int Health. 1996; 1(5):581–9. PMID: 8911442
5. Basáñez MG, Pion SDS, Boakes E, Filipe JA, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on *Onchocerca volvulus*: a systematic review and meta-analysis. Lancet Infect Dis. 2008; 8(5):310–22. [https://doi.org/10.1016/S1473-3099\(08\)70099-9](https://doi.org/10.1016/S1473-3099(08)70099-9) PMID: 18471776
6. Rodríguez-Pérez MA, Unnasch TR, Domínguez-Vázquez A, Morales-Castro AL, Peña-Flores GP, Orozco-Algarra ME, et al. Interruption of transmission of *Onchocerca volvulus* in the Oaxaca focus,

- Mexico. *Am J Trop Med Hyg.* 2010; 83(1):21–7. <https://doi.org/10.4269/ajtmh.2010.09-0544> PMID: 20595472
7. Rodriguez-Perez MA, Dominguez-Vazquez A, Unnasch TR, Hassan HK, Arredondo-Jimenez JI, Orozco-Algarra ME, et al. Interruption of transmission of *Onchocerca volvulus* in the Southern Chiapas Focus, Mexico. *PLoS Negl Trop Dis.* 2013; 7(3):e2133. <https://doi.org/10.1371/journal.pntd.0002133> PMID: 23556018
8. Gonzalez RJ, Cruz-Ortiz N, Rizzo N, Richards J, Zea-Flores G, Dominguez A, et al. Successful interruption of transmission of *Onchocerca volvulus* in the Escuintla-Guatemala focus, Guatemala. *PLoS Negl Trop Dis.* 2009; 3(3):e404. <https://doi.org/10.1371/journal.pntd.0000404> PMID: 19333366
9. Lovato R, Guevara A, Guderian R, Proano R, Unnasch T, Criollo H, et al. Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution. *PLoS Negl Trop Dis.* 2014; 8(5):e2821. <https://doi.org/10.1371/journal.pntd.0002821> PMID: 24853587
10. Convit J, Schuler H, Borges R, Olivero V, Dominguez-Vazquez A, Frontado H, et al. Interruption of *Onchocerca volvulus* transmission in Northern Venezuela. *Parasit Vectors.* 2013; 6(1):289. <https://doi.org/10.1186/1756-3305-6-289> PMID: 24499653
11. Richards F Jr., Rizzo N, Diaz Espinoza CE, Monroy ZM, Crovella Valdez CG, de Cabrera RM, et al. One hundred years after its discovery in Guatemala by Rodolfo Robles, *Onchocerca volvulus* transmission has been eliminated from the central endemic zone. *Am J Trop Med Hyg.* 2015; 93(6):1295–304. <https://doi.org/10.4269/ajtmh.15-0364> PMID: 26503275
12. Botto C, Basañez MG, Escalona M, Villamizar NJ, Noya-Alarcón O, Cortez J, et al. Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus. *Parasit Vectors.* 2016; 9(1):40.
13. Higazi TB, Zarroug IM, Mohamed HA, Elmubark WA, Deran TC, Aziz N, et al. Interruption of *Onchocerca volvulus* transmission in the Abu Hamed focus, Sudan. *Am J Trop Med Hyg.* 2013; 89(1):51–7. <https://doi.org/10.4269/ajtmh.13-0112> PMID: 23690554
14. Katarbwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, et al. Transmission of onchocerciasis in wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. *J Parasitol Res.* 2012; 2012:748540. <https://doi.org/10.1155/2012/748540> PMID: 22970347
15. Lakwo TL, Garms R, Rubaale T, Katarbwa M, Walsh F, Habomugisha P, et al. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector *Simulium neavei* and 19 years of annual ivermectin treatments. *Acta Trop.* 2013; 126(3):218–21. <https://doi.org/10.1016/j.actatropica.2013.02.016> PMID: 23458325
16. Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. *Parasit Vectors.* 2012; 5:28. <https://doi.org/10.1186/1756-3305-5-28> PMID: 22313631
17. Tekle AH, Zoure HG, Noma M, Boussinesq M, Coffeng LE, Stolk WA, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. *Infect Dis Poverty.* 2016; 5(1):66. <https://doi.org/10.1186/s40249-016-0160-7> PMID: 27349645
18. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Dombia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. *PLoS Negl Trop Dis.* 2012; 6(9):e1825. <https://doi.org/10.1371/journal.pntd.0001825> PMID: 23029586
19. Zarroug IM, Hashim K, Elmubark WA, Shumo ZA, Salih KA, ElNojomi NA, et al. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. *Am J Trop Med Hyg.* 2016.
20. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. Geneva: World Health Organization; 2012.
21. Eighteenth session of the Joint Action Forum (JAF) of the African Programme for Onchocerciasis Control, Bujumbura, Burundi, 11–13 December 2012. Final communiqué. Africa Programme for Onchocerciasis Control (APOC); 2012.
22. Borsboom GJ, Boatín BA, Nagelkerke NJ, Agoua H, Akpoboua KL, Alley EW, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. *Filaria J.* 2003; 2(1):8. <https://doi.org/10.1186/1475-2883-2-8> PMID: 12769825
23. Remme J, Baker RH, De Sole G, Dadzie KY, Walsh JF, Adams MA, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of *Onchocerca volvulus*. *Trop Med Parasitol.* 1989; 40(3):367–74. PMID: 2617046

24. Lakwo TL. Preliminary studies on the biting activity and transmission of *Onchocerca volvulus* by *Simulium neavei* (diptera: simuliidae) in Kashoya-Kitomi focus, Western Uganda. *East Afr Med J*. 2004; 81(5):244–7. PMID: [15508338](#)
25. Katarbarwa M, Eyamba A, Habomugisha P, Lakwo T, Ekobo S, Kamgno J, et al. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. *Trop Med Int Health*. 2008; 13(9):1196–203. <https://doi.org/10.1111/j.1365-3156.2008.02126.x> PMID: [18631308](#)
26. Katarbarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagai J, et al. Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon. *Am J Trop Med Hyg*. 2011; 85(6):1041–9. <https://doi.org/10.4269/ajtmh.2011.11-0333> PMID: [22144441](#)
27. Frempong KK, Walker M, Cheke RA, Teteve EJ, Gyan ET, Owusu EO, et al. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of River Blindness? *Clin Infect Dis*. 2016; 62(11):1338–47. <https://doi.org/10.1093/cid/ciw144> PMID: [27001801](#)
28. Eisenbarth A, Achukwi MD, Renz A. Ongoing transmission of *Onchocerca volvulus* after 25 years of annual ivermectin mass treatments in the Vina du Nord River Valley, in North Cameroon. *PLoS Negl Trop Dis*. 2016; 10(2):e0004392. <https://doi.org/10.1371/journal.pntd.0004392> PMID: [26926855](#)
29. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol*. 2004; 98(4):359–70. <https://doi.org/10.1179/000349804225003442> PMID: [15228717](#)
30. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol*. 2004; 98(3):231–49. <https://doi.org/10.1179/000349804225003253> PMID: [15119969](#)
31. Lamberton PHL, Cheke RA, Winskill P, Tirados I, Walker M, Osei-Atweneboana MY, et al. Onchocerciasis Transmission in Ghana: Persistence under Different Control Strategies and the Role of the Simuliid Vectors. *PLoS Negl Trop Dis*. 2015; 9(4):e0003688. <https://doi.org/10.1371/journal.pntd.0003688> PMID: [25897492](#)
32. Kamga G-R, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Mbigha-Ghogomu S, Souopgui J, et al. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. *Parasit Vectors*. 2016; 9(1):581. <https://doi.org/10.1186/s13071-016-1868-8> PMID: [27842567](#)
33. Koala L, Nikiema A, Post RJ, Paré AB, Kafando CM, Drabo F, et al. Recrudescence of onchocerciasis in the Comoé valley in Southwest Burkina Faso. *Acta Tropica*. 2017; 166:96–105. <https://doi.org/10.1016/j.actatropica.2016.11.003> PMID: [27845063](#)
34. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evidence of emerging ivermectin resistance in *Onchocerca volvulus*. *PLoS Negl Trop Dis*. 2011; 5(3):e998. <https://doi.org/10.1371/journal.pntd.0000998> PMID: [21468315](#)
35. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of *Onchocerca volvulus* infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. *Lancet*. 2007; 369(9578):2021–9. [https://doi.org/10.1016/S0140-6736\(07\)60942-8](https://doi.org/10.1016/S0140-6736(07)60942-8) PMID: [17574093](#)
36. Pion SDS, Nana-Djeunga HC, Kamgno J, Tendongfor N, Wanji S, Njiokou F, et al. Dynamics of *Onchocerca volvulus* microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from Cameroon. *PLoS Negl Trop Dis*. 2013; 7(2):e2084. <https://doi.org/10.1371/journal.pntd.0002084> PMID: [23469307](#)
37. Nana-Djeunga HC, Bourguinat C, Pion SDS, Bopda J, Kengne-Ouafo JA, Njiokou F, et al. Reproductive status of *Onchocerca volvulus* after ivermectin treatment in an ivermectin-naïve and a frequently treated population from Cameroon. *PLoS Negl Trop Dis*. 2014; 8(4):e2824. <https://doi.org/10.1371/journal.pntd.0002824> PMID: [24762816](#)
38. Osei-Atweneboana MY, Boakye DA, Awadzi K, Gyapong JO, Prichard RK. Genotypic analysis of beta-tubulin in *Onchocerca volvulus* from communities and individuals showing poor parasitological response to ivermectin treatment. *Int J Parasitol Drugs Drug Resist*. 2012; 2.
39. Ardelli BF, Guerriero SB, Prichard RK. Genomic organization and effects of ivermectin selection on *Onchocerca volvulus* P-glycoprotein. *Mol Biochem Parasitol*. 2005; 143(1):58–66. <https://doi.org/10.1016/j.molbiopara.2005.05.006> PMID: [15993957](#)
40. Ardelli BF, Guerriero SB, Prichard RK. Ivermectin imposes selection pressure on P-glycoprotein from *Onchocerca volvulus*: linkage disequilibrium and genotype diversity. *Parasitology*. 2006; 132(Pt 3):375–86. <https://doi.org/10.1017/S0031182005008991> PMID: [16280093](#)

41. Ardelli BF, Guerriero SB, Prichard RK. Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in *Onchocerca volvulus*. *Mol Biochem Parasitol*. 2006; 145(1):94–100. <https://doi.org/10.1016/j.molbiopara.2005.09.011> PMID: 16257066
42. Ardelli BF, Prichard RK. Identification of variant ABC-transporter genes among *Onchocerca volvulus* collected from ivermectin-treated and untreated patients in Ghana, West Africa. *Ann Trop Med Parasitol*. 2004; 98(4):371–84. <https://doi.org/10.1179/000349804225003415> PMID: 15228718
43. Ardelli BF, Prichard RK. Reduced genetic variation of an *Onchocerca volvulus* ABC transporter gene following treatment with ivermectin. *Trans R Soc Trop Med Hyg*. 2007; 101(12):1223–32. <https://doi.org/10.1016/j.trstmh.2005.03.019> PMID: 17904599
44. Bourguinat C, Ardelli BF, Pion SD, Kamgno J, Gardon J, Duke BO. P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in *Onchocerca volvulus*. *Mol Biochem Parasitol*. 2008; 158.
45. Bottomley C, Isham V, Collins RC, Basáñez MG. Rates of microfilarial production by *Onchocerca volvulus* are not cumulatively reduced by multiple ivermectin treatments. *Parasitology*. 2008; 135(13):1571–81. <https://doi.org/10.1017/S0031182008000425> PMID: 18831801
46. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in *Onchocerca volvulus* infection. *PLoS Negl Trop Dis*. 2014; 8(6):e2953. <https://doi.org/10.1371/journal.pntd.0002953> PMID: 24968000
47. Bakajika DK, Kanza E, Howard H, Opoku N, Tchatchu J-PL, Kataliko K, et al., editors. Is *O. volvulus* suboptimal response to ivermectin a result of selection under ivermectin pressure? Insights from a study comparing ivermectin and moxidectin in areas without prior ivermectin mass treatment. *Am J Trop Med Hyg*; 2013; Washington, DC.
48. Pion SDS, Grout L, Kamgno J, Nana-Djeunga H, Boussinesq M. Individual host factors associated with *Onchocerca volvulus* microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. *Acta Trop*. 2011; 120 Suppl 1:S91–9.
49. Burnham G. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet*. 2007; 370(9593):1125.
50. Cupp E, Richards F, Lammie P, Eberhard M. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet*. 2007; 370(9593):1123; author reply 4–5.
51. Mackenzie CD. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet*. 2007; 370(9593):1123; author reply 4–5.
52. Remme JH, Amazigo U, Engels D, Barryson A, Yameogo L. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet*. 2007; 370(9593):1123–4; author reply 4–5.
53. Hotez PJ. Control of onchocerciasis—the next generation. *Lancet*. 2007; 369(9578):1979–80. [https://doi.org/10.1016/S0140-6736\(07\)60923-4](https://doi.org/10.1016/S0140-6736(07)60923-4) PMID: 17574078
54. Churcher TS, Pion SDS, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. *Proc Natl Acad Sci U S A*. 2009; 106(39):16716–21. <https://doi.org/10.1073/pnas.0906176106> PMID: 19805362
55. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG. Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. *PLoS Negl Trop Dis*. 2013; 7(4):e2169. <https://doi.org/10.1371/journal.pntd.0002169> PMID: 23634234
56. Park DJ, Lukens AK, Neafsey DE, Schaffner SF, Chang HH, Valim C, et al. Sequence-based association and selection scans identify drug resistance loci in the *Plasmodium falciparum* malaria parasite. *Proc Natl Acad Sci U S A*. 2012; 109(32):13052–7. <https://doi.org/10.1073/pnas.1210585109> PMID: 22826220
57. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome region underlying artemisinin resistance in malaria. *Science*. 2012; 336(6077):79–82. <https://doi.org/10.1126/science.1215966> PMID: 22491853
58. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Nat Genet*. 2013; 45(6):648–55. <https://doi.org/10.1038/ng.2624> PMID: 23624527
59. Cheeseman IH, McDew-White M, Phyto AP, Sriprawat K, Nosten F, Anderson TJ. Pooled sequencing and rare variant association tests for identifying the determinants of emerging drug resistance in malaria parasites. *Mol Biol Evol*. 2015; 32(4):1080–90. <https://doi.org/10.1093/molbev/msu397> PMID: 25534029
60. Chang H-H, Moss EL, Park DJ, Ndiaye D, Mboup S, Volkman SK, et al. Malaria life cycle intensifies both natural selection and random genetic drift. *Proceedings of the National Academy of Sciences*. 2013; 110(50):20129–34.

61. Valentim CL, Cioli D, Chevalier FD, Cao X, Taylor AB, Holloway SP, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. *Science*. 2013; 342(6164):1385–9. <https://doi.org/10.1126/science.1243106> PMID: 24263136
62. Downing T, Imamura H, Decuyper S, Clark TG, Coombs GH, Cotton JA, et al. Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. *Genome Res*. 2011; 21(12):2143–56. <https://doi.org/10.1101/gr.123430.111> PMID: 22038251
63. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, Goodhead I, et al. High-throughput sequencing provides insights into genome variation and evolution in *Salmonella Typhi*. *Nat Genet*. 2008; 40(8):987–93. <https://doi.org/10.1038/ng.195> PMID: 18660809
64. Gilleard JS. Understanding anthelmintic resistance: The need for genomics and genetics. *Int J Parasitol*. 2006; 36(12):1227–39. <https://doi.org/10.1016/j.ijpara.2006.06.010> PMID: 16889782
65. Kotze AC, Hunt PW, Skuce P, von Samson-Himmelstjerna G, Martin RJ, Sager H, et al. Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions. *Int J Parasitol Drugs Drug Resist*. 2014; 4(3):164–84. <https://doi.org/10.1016/j.ijpddr.2014.07.007> PMID: 25516826
66. Choi Y-J, Tyagi R, McNulty SN, Rosa BA, Ozersky P, Martin J, et al. Genomic diversity in *Onchocerca volvulus* and its *Wolbachia* endosymbiont. *Nat Microbiol*. 2016; 2:16207. <https://doi.org/10.1038/nmicrobiol.2016.207> PMID: 27869792
67. Meredith SEO, Lando G, Gbakima AA, Zimmerman PA, Unnasch TR. *Onchocerca volvulus*—Application of the Polymerase Chain-Reaction to Identification and Strain Differentiation of the Parasite. *Exp Parasitol*. 1991; 73(3):335–44. PMID: 1915748
68. Zimmerman PA, Dadzie KY, Desole G, Remme J, Alley ES, Unnasch TR. *Onchocerca volvulus* DNA probe classification correlates with epidemiologic patterns of blindness. *J Infect Dis*. 1992; 165(5):964–8. PMID: 1569351
69. Bottomley C, Isham V, Vivas-Martínez S, Kuesel AC, Attah SK, Opoku NO, et al. Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for *Onchocerca volvulus* in near elimination and surveillance settings. *Parasit Vectors*. 2016; 9(1):343. <https://doi.org/10.1186/s13071-016-1605-3> PMID: 27301567
70. Cotton JA, Bennuru S, Grote A, Harsha B, Tracey A, Beech R, et al. The genome of *Onchocerca volvulus*, agent of river blindness. *Nat Microbiol*. 2016; 2:16216. <https://doi.org/10.1038/nmicrobiol.2016.216> PMID: 27869790
71. Bennuru S, Cotton JA, Ribeiro JM, Grote A, Harsha B, Holroyd N, et al. Stage-specific transcriptome and proteome analyses of the filarial parasite *Onchocerca volvulus* and its *Wolbachia* endosymbiont. *MBio*. 2016; 7(6).
72. Howe KL, Bolt BJ, Shafie M, Kersey P, Berriman M. WormBase ParaSite – a comprehensive resource for helminth genomics. *Mol Biochem Parasitol*. 2016; In press: Available online 27 November 2016.
73. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv preprint arXiv:13033997*. 2013.
74. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011; 43(5):491–8. <https://doi.org/10.1038/ng.806> PMID: 21478889
75. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010; 20(9):1297–303. <https://doi.org/10.1101/gr.107524.110> PMID: 20644199
76. Bansal V. A statistical method for the detection of variants from next-generation resequencing of DNA pools. *Bioinformatics*. 2010; 26(12):i318–24. <https://doi.org/10.1093/bioinformatics/btq214> PMID: 20529923
77. Kofler R, Pandey RV, Schlötterer C. PoPoolation2: identifying differentiation between populations using sequencing of pooled DNA samples (Pool-Seq). *Bioinformatics*. 2011; 27(24):3435–6. <https://doi.org/10.1093/bioinformatics/btr589> PMID: 22025480
78. Storm N, Darnhofer-Patel B, van den Boom D, Rodi CP. MALDI-TOF mass spectrometry-based SNP genotyping. *Methods Mol Biol*. 2003; 212:241–62. PMID: 12491915
79. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81(3):559–75. <https://doi.org/10.1086/519795> PMID: 17701901
80. Jombart T. adegenet: a R package for the multivariate analysis of genetic markers. *Bioinformatics*. 2008; 24(11):1403–5. <https://doi.org/10.1093/bioinformatics/btn129> PMID: 18397895

81. Duke BO. The population dynamics of *Onchocerca volvulus* in the human host. *Trop Med Parasitol*. 1993; 44(2):61–8. PMID: [8367667](#)
82. Duerr HP, Dietz K, Schulz-Key H, Buttner DW, Eichner M. The relationships between the burden of adult parasites, host age and the microfilarial density in human onchocerciasis. *Int J Parasitol*. 2004; 34(4):463–73. <https://doi.org/10.1016/j.ijpara.2003.11.008> PMID: [15013736](#)
83. Rellstab C, Zoller S, Tedder A, Gugerli F, Fischer MC. Validation of SNP allele frequencies determined by pooled next-generation sequencing in natural populations of a non-model plant species. *PLoS One*. 2013; 8(11):e80422. <https://doi.org/10.1371/journal.pone.0080422> PMID: [24244686](#)
84. Kim SY, Li Y, Guo Y, Li R, Holmkvist J, Hansen T, et al. Design of association studies with pooled or un-pooled next-generation sequencing data. *Genet Epidemiol*. 2010; 34(5):479–91. <https://doi.org/10.1002/gepi.20501> PMID: [20552648](#)
85. Futschik A, Schlötterer C. The next generation of molecular markers from massively parallel sequencing of pooled DNA samples. *Genetics*. 2010; 186(1):207–18. <https://doi.org/10.1534/genetics.110.114397> PMID: [20457880](#)
86. Schlötterer C, Tobler R, Kofler R, Nolte V. Sequencing pools of individuals—mining genome-wide polymorphism data without big funding. *Nat Rev Genet*. 2014; 15(11):749–63. <https://doi.org/10.1038/nrg3803> PMID: [25246196](#)
87. Anderson EC, Skaug HJ, Barshis DJ. Next-generation sequencing for molecular ecology: a caveat regarding pooled samples. *Mol Ecol*. 2014; 23(3):502–12. <https://doi.org/10.1111/mec.12609> PMID: [24304095](#)
88. Lynch M, Bost D, Wilson S, Maruki T, Harrison S. Population-genetic inference from pooled-sequencing data. *Genome Biol Evol*. 2014; 6(5):1210–8. <https://doi.org/10.1093/gbe/evu085> PMID: [24787620](#)
89. Kofler R, Orozco-terWengel P, De Maio N, Pandey RV, Nolte V, Futschik A, et al. PoPoolation: a toolbox for population genetic analysis of next generation sequencing data from pooled individuals. *PLoS One*. 2011; 6(1):e15925. <https://doi.org/10.1371/journal.pone.0015925> PMID: [21253599](#)
90. Traore-Lamizana M, Lemasson J. Participation à une étude de faisabilité d'une campagne de lutte contre l'onchocercose dans la région du bassin du Logone: répartition des espèces du complexe *Simulium damnosum* dans la zone camerounaise du projet. *Cahiers-ORSTOM Entomologie médicale et parasitologie*. 1988; 25(3–4):171–86.
91. Basáñez MG, Churcher TS, Grillet ME. *Onchocerca-Simulium* interactions and the population and evolutionary biology of *Onchocerca volvulus*. *Adv Parasitol*. 2009; 68.
92. Cully DF, Vassilatis DK, Liu KK, Paress PS, Vanderploeg LHT, Schaeffer JM, et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from *Caenorhabditis elegans*. *Nature*. 1994; 371(6499):707–11. <https://doi.org/10.1038/371707a0> PMID: [7935817](#)
93. Bany IA, Dong MQ, Koelle MR. Genetic and cellular basis for acetylcholine inhibition of *Caenorhabditis elegans* egg-laying behavior. *J Neurosci*. 2003; 23(22):8060–9. PMID: [12954868](#)
94. Ringstad N, Horvitz HR. FMRFamide neuropeptides and acetylcholine synergistically inhibit egg-laying by *C. elegans*. *Nat Neurosci*. 2008; 11(10):1168–76. <https://doi.org/10.1038/nn.2186> PMID: [18806786](#)
95. Waggoner LE, Zhou GT, Schafer RW, Schafer WR. Control of alternative behavioral states by serotonin in *Caenorhabditis elegans*. *Neuron*. 1998; 21(1):203–14. PMID: [9697864](#)
96. Li B-W, Rush AC, Weil GJ. Expression of five acetylcholine receptor subunit genes in *Brugia malayi* adult worms. *Int J Parasitol Drugs Drug Resist*. 2015; 5(3):100–9. <https://doi.org/10.1016/j.ijpddr.2015.04.003> PMID: [26199859](#)
97. Hernando G, Bouzat C. *Caenorhabditis elegans* neuromuscular junction: GABA receptors and ivermectin action. *PLoS One*. 2014; 9(4):e95072. <https://doi.org/10.1371/journal.pone.0095072> PMID: [24743647](#)
98. Abongwa M, Buxton SK, Robertson AP, Martin RJ. Curiouser and curiouser: The macrocyclic lactone, abamectin, is also a potent inhibitor of pyrantel/tribendimidine nicotinic acetylcholine receptors of gastro-intestinal worms. *PLoS One*. 2016; 11(1).
99. Bourguinat C, Pion SDS, Kamgno J, Gardon J, Duke BOL, Boussinesq M, et al. Genetic selection of low fertile *Onchocerca volvulus* by ivermectin treatment. *PLoS Negl Trop Dis*. 2007; 1(1).
100. Laing ST, Ivens A, Butler V, Ravikumar SP, Laing R, Woods DJ, et al. The transcriptional response of *Caenorhabditis elegans* to ivermectin exposure identifies novel genes involved in the response to reduced food intake. *PLoS One*. 2012; 7(2):e31367. <https://doi.org/10.1371/journal.pone.0031367> PMID: [22348077](#)
101. Bourguinat C, Lee AC, Lizundia R, Blagburn BL, Liotta JL, Kraus MS, et al. Macrocyclic lactone resistance in *Dirofilaria immitis*: Failure of heartworm preventives and investigation of genetic markers for

- p>resistance.
- Vet Parasitol.*
- 2015; 210(3–4):167–78.
- <https://doi.org/10.1016/j.vetpar.2015.04.002>
- PMID: 25936435
102. Choi YJ, Bisset SA, Doyle SR, Hallsworth-Pepin K, Martin J, Grant WN, et al. Genomic introgression mapping of field-derived multiple-anthelmintic resistance in the nematode parasite *Teladorsagia circumcincta*. *PLoS Genet.* 2017; 13:e1006857
 103. Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK. Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. *Vet Parasitol.* 2011; 176(4):374–81. <https://doi.org/10.1016/j.vetpar.2011.01.024> PMID: 21300438
 104. Hunt PW. Identification and characterisation of dominant ivermectin resistant genes in *Caenorhabditis elegans* [PhD thesis]: University of New England; 1995.
 105. Barnes TM, Hekimi S. The *Caenorhabditis elegans* avermectin resistance and anesthetic response gene *unc-9* encodes a member of a protein family implicated in electrical coupling of excitable cells. *J Neurochem.* 1997; 69(6):2251–60. PMID: 9375655
 106. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: An economic evaluation of increasing the frequency of ivermectin treatment in Africa. *Clin Infect Dis.* 2014; 59(7):923–32. <https://doi.org/10.1093/cid/ciu467> PMID: 24944228
 107. Stolk WA, Walker M, Coffeng LE, Basáñez MG, de Vlas SJ. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. *Parasit Vectors.* 2015; 8(1):552.
 108. Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, et al. Elimination of African onchocerciasis: Modeling the impact of increasing the frequency of ivermectin mass treatment. *PLoS One.* 2015; 9(12):e115886.
 109. Doyle SR, Armoo S, Renz A, Taylor MJ, Osei-Atweneboana MY, Grant WN. Discrimination between *Onchocerca volvulus* and *O. ochengi* filarial larvae in *Simulium damnosum* (s.l.) and their distribution throughout central Ghana using a versatile high-resolution speciation assay. *Parasit Vectors.* 2016; 9(1):536. <https://doi.org/10.1186/s13071-016-1832-7> PMID: 27724959
 110. Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-*Wolbachia* drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. *Parasitology.* 2014; 141(1):119–27. <https://doi.org/10.1017/S0031182013001108> PMID: 23866958
 111. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. *Clinical Infectious Diseases.* 2015; 60(8):1199–207. <https://doi.org/10.1093/cid/ciu1152> PMID: 25537873
 112. Turner HC, Walker M, Attah SK, Opoku NO, Awadzi K, Kuesel AC, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. *Parasit Vectors.* 2015; 8(1):167.
 113. Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. *Int J Parasitol Drugs Drug Resist.* 2016; Volume 6(Issue 3):272–86.
 114. African Programme for Onchocerciasis Control (APOC): Strategic options and alternative treatment strategies for accelerating onchocerciasis elimination in Africa. Ouagadougou: World Health Organization 2015.